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Cannabis Derivatives and Trademark Registration: The
Case of Delta-8-THC
W. MICHAEL SCHUSTER*
The legal environment surrounding the cannabis industry is ambiguous and
constantly changing. While cannabis is prohibited under federal law, a 2018 statute
legalized a variant of the cannabis plant (“hemp”) that is low in its most common
intoxicating agents. Recognizing this, entrepreneurs began to process hemp to
extract and sell chemicals contained therein. Included in this trend is the extraction
of Delta-8 Tetrahydrocannabinol (Δ8-THC)—a psychoactive drug with an
increasing market presence in states where most cannabis (e.g., “marijuana”) is
illegal.
As competition in the Δ8-THC field emerged, firms sought to distinguish their
wares through brand recognition and federal trademark registration. However, the
U.S. Patent and Trademark Office refuses to register these marks—arguing that Δ8THC does not satisfy the requirement that products be used “in legal commerce.”
On this point, the USPTO interprets relevant law as criminalizing the sale of Δ8THC. That conclusion stands in contrast to determinations reached by the Drug
Enforcement Agency and federal courts.
This Article addresses the propriety of federal registration of Δ8-THC
trademarks. It critically analyzes the intersection of federal drug law, hemp’s
legalization, and administrative regulations to answer the question. Based on this
research, a strong case for the registration of Δ8-THC marks1 arises. This
conclusion has public and private importance.
To seek registration of a Δ8-THC mark, applicants must aver that they use it in
commerce. This could amount to admitting to the sale of an illegal drug—depending
on the interpretation of somewhat ambiguous regulations. With this in mind, a law
and strategy analysis is employed to explain why firms take that risk to seek
trademark registration. On this issue, the Article identifies specific current market
advantages and future strategic gains that warrant this exposure.
Further, public benefits of Δ8-THC registration are explored. A current concern
in this largely unregulated market is the presence of harmful impurities in goods sold
for human consumption. This issue can be mitigated by aligning the public interest
in safe products with private financial incentives. Specifically, the ability to maintain
strong trademark rights encourages the creation of goodwill through the sale of
quality products. Recognizing this, firms are encouraged to reduce impurities in
their Δ8-THC wares under the belief that this will benefit their reputation and thus
increase sales.

* Mike Schuster is an assistant professor at the University of Georgia Terry College of
Business with a courtesy appointment at the University of Georgia School of Law.
1. The term “mark” is used herein as shorthand for “trademark.”

178

INDIANA LAW JOURNAL

[Vol. 98:177

INTRODUCTION....................................................................................................... 178
I. CANNABIS REGULATION AND TRADEMARK LAW ............................................... 180
A. CANNABIS AND THE CONTROLLED SUBSTANCES ACT ............................. 180
B. CANNABIDIOL (CBD)............................................................................... 183
C. DELTA-8 THC .......................................................................................... 185
D. STATE REGULATION ................................................................................ 189
E. TRADEMARK LAW .................................................................................... 192
1. FEDERAL PROTECTION .................................................................... 192
2. STATE PROTECTION ......................................................................... 193
II. THE USPTO AND CANNABIS-RELATED TRADEMARK APPLICATIONS ............... 195
A. CBD TRADEMARKS ................................................................................. 195
B. TREATMENT OF Δ8-THC TRADEMARK APPLICATIONS ............................ 197
C. USPTO POLICIES FAVOR Δ8-THC REGISTRATION .................................. 200
III. THE IMPORTANCE OF DELTA-8 THC REGISTRATIONS ..................................... 203
A. PRIVATE STRATEGIC BENEFITS ................................................................ 204
B. POTENTIAL BENEFITS FOR THE CONSUMING PUBLIC ............................... 210
CONCLUSION .......................................................................................................... 212
INTRODUCTION
Regulation of the cannabis industry is fraught with uncertainty and uneven
enforcement. Prior research generally describes how firms navigate the market’s
ambiguous legal environment to create strategic advantage. This Article focuses the
earlier literature by analyzing public and private behaviors at the uncertain
intersection of trademark law and cannabis derivatives.
Delta-8 Tetrahydrocannabinol (Δ8-THC) is a chemical occurring in low
concentrations in the cannabis plant.2 It can be extracted in commercially viable
quantities through a chemical process.3 Like many compounds found in cannabis,
Δ8-THC is psychoactive (e.g., it elicits a “high”).4 However, unlike the most
common active agents in cannabis—such as Delta-9 Tetrahydrocannabinol—Δ8THC is arguably legal under federal law. Recognizing this possibility, firms have
entered the Δ8-THC market,5 especially in states where cannabis is not generally
legal.6

2. Sierra McWilliams, Andrew Goff & Erin Williams, Regulatory Challenge of New
Hemp Products—Delta-8 THC and Other Cannabinoids, in CANNABIS LAW DESKBOOK §
25:11 (Austin Bernstein & Bruce Turcott eds., 2021–2022 ed.) (“Delta-8 THC, as opposed to
delta-9 THC, is a cannabinoid usually found in very trace amounts in cannabis plants.”).
3. See Eric C. Leas, The Hemp Loophole: A Need to Clarify the Legality of Delta-8-THC
and Other Hemp-Derived Tetrahydrocannabinol Compounds, 111 AM. J. PUB. HEALTH 1927,
1927 (2021) (“Because CBD isomers are similar in structure to THC isomers, they can be
converted to THC isomers through a relatively simple series of chemical reactions.”).
4. See Leas, supra note 3.
5. See AK Futures LLC v. Boyd St. Distro, LLC, 35 F.4th 682, 695 (9th Cir. 2022)
(holding Plaintiff’s delta-THC products are lawful under the plain text of the Farm Act and
may receive trademark protection; therefore, affirming the grant of a preliminary injunction).
6. See generally Melvin D. Livingston, Andrew Walker, Michael B. Cannell & Matthew
E. Rossheim, Popularity of Delta-8 THC on the Internet Across US States, 2021, 112 AM. J.
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As competition in this nascent field emerged, companies began to seek trademark
protection for their Δ8-THC wares. The U.S. Patent and Trademark Office (USPTO
or “Trademark Office”) refuses, however, to register these marks. 7 It maintains a
policy that marks must be used “in legal commerce” to be registered, and the
Trademark Office believes Δ8-THC is illegal under the Controlled Substances Act
(CSA).8 Its position differs from other governmental bodies, including the Drug
Enforcement Administration (DEA).
This Article makes two contributions to this uncertain legal environment. First,
Part I examines Δ8-THC’s legal status under the Controlled Substances Act and the
2018 Farm Bill. The latter deregulated a low-intoxicant form of cannabis called
“hemp,” which arguably legalized Δ8-THC derived from hemp. This position has,
however, received differing treatment by the courts, DEA, and Trademark Office.
Recognizing this divergence, Part 0 evaluates how trademark applications for Δ8THC should be treated. The analysis finds that based on principles of statutory
interpretation, administrative deference, and the Trademark Office’s own policies
and precedent, these marks ought to be registered.
Part 0 then analyzes the private strategic importance of Δ8-THC trademarks and
public benefits that may arise if they are registered. Applying a law and strategy
approach, this part analyzes the actions of Δ8-THC firms as they seek trademark
registrations to secure immediate competitive advantage and future strategic gains.
The discussion concludes by describing why registration of these trademarks aligns
public and private incentives to ensure that the Δ8-THC available to the public is
safe for consumption.

PUB. HEALTH 296, 297 (2022) (describing increased interest in Δ8-THC in states where
recreational cannabis is illegal that may indicate increased consumption).
7. See, e.g., Letter from Christina Calloway, Examining Attorney, U.S. Pat. &
Trademark Off., to Liam Burns, Bearly Legal Hemp (Oct. 21, 2020) (U.S. Application Serial
No. 90036541) (rejecting a Δ8-THC related application for failure to comply with the
Controlled Substances Act); Letter from Alexandra El-Bayeh, Examining Attorney, U.S. Pat.
& Trademark Off., to Jas Sum Kral, Inc. (Oct. 18, 2021) (U.S. Application Serial No.
90289354) (same); Letter from Alexandra El-Bayeh, Examining Attorney, U.S. Pat. &
Trademark Off., to Science Holdings, LLC (Aug. 4, 2021) (U.S. Application Serial No.
90251954) (same); Letter from Jeffrey Look, Examining Attorney, U.S. Pat. & Trademark
Off., to Matthew McKinney, STNR Creations, LLC (Aug. 4, 2021) (U.S. Application Serial
No. 90160477) (same).
8. This Article only addresses Δ8-THC trademark issues with regard to legal use in
commerce and the Controlled Substances Act. Some Δ8-THC marks also face issues with
Food, Drug and Cosmetic Act (FDCA) compliance and the legal use in commerce
requirement, though this is beyond the scope of the current research. See Letter from Jeffrey
Look, Examining Attorney, U.S. Pat. & Trademark Off., to Matthew McKinney, STNR
Creations, LLC (Aug. 4, 2021) (U.S. Application Serial No. 90160477) (Under the FDCA,
“[i]t is unlawful to introduce food to which CBD, an article that is approved as a new drug,
has been added into interstate commerce or to market CBD as, or in, dietary supplements,
regardless of whether the substances are hemp-derived.”) (internal quotation marks omitted).
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I. CANNABIS REGULATION AND TRADEMARK LAW
This Part discusses two fields of the law that are integral to this Article. First, the
analysis looks to the federal and state regulation of cannabis. A brief history of
cannabis’s prohibition is given, followed by a discussion of modern regulation and
the movement toward legalization. The second Part addresses trademark law and its
importance in generating brand recognition. Both federal and state regimes are
introduced to prepare for future discussion of apparent inconsistencies in the current
treatment of Δ8-THC goods.
A. Cannabis and the Controlled Substances Act
Marijuana and its derivatives come from the Cannabis sativa plant—generally
referred to as “cannabis” herein.9 The plant’s leaves and flowers are harvested to
create these drugs.10 The primary psychoactive agent in cannabis is delta-9
tetrahydrocannabinol,11 which may cause euphoria and distorted perception.12 The
“delta-9” connotation references the location of a carbon-carbon double bond within
the chemical—an important nuance that we will return to shortly.13 The drug has
medical uses including nausea relief and treatment of anorexia and neuropathic
pain,14 though side effects include paranoia, anxiety, and headaches.15
Cannabis was first used recreationally in the United States in the early 1900s.16
Early prohibitions followed, with Utah and California both outlawing the drug by

9. Itai Danovitch, Sorting Through the Science on Marijuana: Facts, Fallacies, and
Implications for Legalization, 43 MCGEORGE L. REV. 91, 93 (2012).
10. See United States v. Osburn, 955 F.2d 1500, 1503 n.2 (11th Cir. 1992).
11. Leas, supra note 3; see also Danovitch, supra note 9, at 93 (citing Raphael
Mechoulam, Arnon Shani, Habib Edery & Yona Grunfeld, Chemical Basis of Hashish
Activity, 169 SCI. 611, 611–12 (1970)). There are eighty-five or more activated chemicals in
cannabis, including Δ9-THC. Daniel Cressey, The Cannabis Experiment, 524 NATURE 280,
282 (2015). “Because of delta-9-THC’s ubiquity in most cannabis strains, it is often referred
to universally as ‘THC,’” though as will be discussed later, other variants of THC can occur
in (usually) smaller amounts. Leas, supra note 3.
12. Groves v. Comm'r of Soc. Sec., No. 1:09-cv-00537, 2010 WL 3154343, at *4 n.19
(E.D. Cal. Aug. 6, 2010).
13. Leas, supra note 3 (“Delta-8-THC is nearly identical in chemical structure to delta-9THC, differing only by the location of a carbon–carbon double bond.”).
14. Danovitch, supra note 9, at 94.
15. Troy Farah, Delta-8-THC Promises to Get You High Without the Paranoia or Anxiety,
DISCOVER (July 24, 2022, 5:25 PM), https://www.discovermagazine.com/health/delta-8-thcpromises-to-get-you-high-without-the-paranoia-or-anxiety [https://perma.cc/X4PV-2GTT]
(stating that cannabis “can sometimes spark paranoia and anxiety or trigger dizziness and
headaches”).
16. Laura M. Rojas, California's Compassionate Use Act and the Federal Government's
Medical Marijuana Policy: Can California Physicians Recommend Marijuana to Their
Patients Without Subjecting Themselves to Sanctions?, 30 MCGEORGE L. REV. 1373, 1378
n.40 (1999); Allison E. Don, Note, Lighten Up: Amending the Single Convention on Narcotic
Drugs, 23 MINN. J. INT’L L. 213, 216–17 (2014).
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1915,17 and most states followed suit within twenty-five years.18 Modern federal
regulation began with the passage of the 1970 Comprehensive Drug Abuse
Prevention and Control Act (“Controlled Substances Act”),19 though federal taxes
had previously been used to discourage use.20
The Controlled Substances Act divides drugs into five schedules (I–V).21 Crimes
associated with Schedule I substances bear the greatest penalties,22 as these drugs are
considered to have no medical use and a high risk of abuse.23 Cannabis is included
in Schedule I, alongside drugs like heroin, lysergic acid diethylamide (LSD), and
peyote.24 Federal law broadly criminalizes the manufacture and distribution of drugs
in Schedule I.25 This prohibition includes medical uses.26
Federal law allocates the power to place drugs into a particular schedule to the
Attorney General,27 but that authority has been delegated to the DEA.28 This
discretion can, however, be circumscribed by congressional mandate.29 Indeed, that

17. Daniel J. Pfeifer, Smoking Gun: The Moral and Legal Struggle for Medical
Marijuana, 27 TOURO L. REV. 339, 362 (2011); RICHARD JAY MOLLER, MARIJUANA: YOUR
LEGAL RIGHTS 11 (Ralph Warner ed., 1981).
18. See Allison M. Busby, Seeking a Second Opinion: How to Cure Maryland's Medical
Marijuana Law, 40 U. BALT. L. REV. 139, 144 (2010).
19. See, e.g., 21 U.S.C. § 801 (2012); Cooking Up Solutions to a Cooked Up Menace:
Responses to Methamphetamine in a Federal System, 119 HARV. L. REV. 2508, 2516 (2006).
20. Busby, supra note 18 (“[T]he federal government also began regulating marijuana
under the Marihuana Tax Act of 1937, attempting to curb used of the drug through heavy
taxes.”); see also Richard J. Bonnie & Charles H. Whitebread, II, The Forbidden Fruit and
the Tree of Knowledge: An Inquiry into the Legal History of American Marijuana Prohibition,
56 VA. L. REV. 971, 1053–54 (1970)). Other commenters assert that this taxation scheme was
intended to raise funds, as opposed to discouraging use. See Lauren Males, Current Trends in
Marijuana Regulation, 6 HLRE: OFF THE RECORD 185, 187 (2016) (stating that the “primary
purpose of drug laws in the United States was raising revenue”).
21. Elizabeth Chiarello, The War on Drugs Comes to the Pharmacy Counter: Frontline
Work in the Shadow of Discrepant Institutional Logics, 40 LAW & SOC. INQUIRY 86, 89 (2015).
22. United States v. Reece, 956 F. Supp. 2d 736, 741 (W.D. La. 2013).
23. Martin D. Carcieri, Obama, the Fourteenth Amendment, and the Drug War, 44
AKRON L. REV. 303, 305 n.11 (2011).
24. See generally 21 C.F.R. § 1308.11 (2016); Controlled Substances: Alphabetical
Order, U.S. DRUG ENF’T ADMIN. (2022), https://www.deadiversion.usdoj.gov/schedules/
orangebook/c_cs_alpha.pdf [https://perma.cc/FDS4-49H9]. Criminal offenses associated with
cannabis derivatives are converted into an equivalent sum of cannabis plant for punishment
purposes. U.S. SENT'G GUIDELINES MANUAL § 2D1.1 n.8(D) (U.S. SENT'G COMM'N 2021).
25. 21 U.S.C. § 841(a) (2012).
26. Id.; Katharine McCarthy, Conant v. Walters: A Misapplication of Free Speech Rights
in the Doctor-Patient Relationship, 56 ME. L. REV. 447, 450 (2004).
27. Reece, 956 F. Supp. 2d at 741 (citing Touby v. United States, 500 U.S. 160, 162
(1991)); see United States v. Caudle, 828 F.2d 1111, 1111–12 (5th Cir. 1987).
28. Reece, 956 F. Supp. 2d at 741 (citing Caudle, 828 F.2d at 1112 n.1).
29. Zarazua v. Ricketts, No. 8:17CV318, 2017 WL 6503395, at *1 (D. Neb. Oct. 2, 2017);
see also Haines v. Fed. Motor Carrier Safety Admin., 814 F.3d 417, 429 (6th Cir. 2016)
(noting that agencies must comply with statutory law).
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authority was invoked in 2018 with the passage of the Agricultural Improvement Act
of 2018 (“2018 Farm Bill” or “Farm Bill”).30
The Farm Bill created a legal distinction between illegal cannabis and “hemp,”
which is a cannabis variant that is low in delta-9 tetrahydrocannabinol.31 Specifically,
the Act defined legal hemp as any part of the cannabis plant “with a delta-9
tetrahydrocannabinol concentration of not more than 0.3% on a dry weight basis”
and any extract from hemp.32 There is some evidence that this carve out was intended
to legalize “industrial” hemp33 to be used to manufacture products including rope,
paper, and cloth.34 Indeed, this goal seems to have been achieved. After the passage

30. Agricultural Improvement Act of 2018, Pub. L. No. 115-334, 132 Stat. 4490, 4908,
5018 (2018).
31. Bogard v. Cnty. Mut. Ins. Co., No. 1:19-CV-00705, 2021 WL 4269991, at *2 (D. Or.
Sept. 20, 2021) (“The statutory scheme . . . is a relatively recent development and, historically,
federal law did not draw a distinction between marijuana and hemp for purposes of the
Controlled Substances Act. The new system, which divides cannabis products into legal hemp
and the still-controlled marijuana, was put in place by the Agricultural Improvement Act of
2018 . . . .”); Sierra McWilliams, Andrew Goff & Erin Williams, Legal Distinctions, in
CANNABIS LAW DESKBOOK § 24:2 (2021-2022 ed.); United States v. Rivera, No. 3:20-CR0020, 2021 WL 3560807, at *3 (D.V.I. Aug. 11, 2021) (“Both marijuana and hemp are plants
of the Cannabis sativa species, but they differ dramatically in the quantity of the psychoactive
substance THC, or delta-9 tetrahydrocannabinol, that they contain.”) (quoting United States
v. Bautista, 989 F.3d 698, 704 (9th Cir. 2021)).
32. Agriculture Improvement Act of 2018, Pub. L. No. 115-334, 132 Stat. 4490, 4908
(2018). “In order to meet the AIA's definition of hemp, and thus qualify for the exception in
the definition of marihuana, a cannabis-derived product must itself contain 0.3% or less
[Delta][FN9]-THC on a dry weight basis. It is not enough that a product is labeled or
advertised as ‘hemp.’” Implementation of the Agriculture Improvement Act of 2018, 85 Fed.
Reg. 51639-01, 51641 (Dec. 20, 2018). The Controlled Substances Act previously made an
exception to the general prohibition on hemp in the Agricultural Act of 2014, which let states
“grow or cultivate [low THC] industrial hemp . . . for purposes of research.” 7 U.S.C. §
5940(a) (2014). Additionally, according to the Controlled Substances Act:
[Cannabis] does not include the mature stalks of such plant, fiber produced from
such stalks, oil or cake made from the seeds of such plant, any other compound,
manufacture, salt, derivative, mixture, or preparation of such mature stalks
(except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of
such plant which is incapable of germination.
21 U.S.C. § 802(16) (2012). This carve out was only of notable value for non-drug purposes,
like the production of “non-drug related commercial products [like] hemp rope and clothing
made from hemp plant fiber.” Marty Bergoffen & Roger Lee Clark, Hemp as an Alternative
to Wood Fiber in Oregon, 11 J. ENV’T L. & LITIG. 119, 134 (1996).
33. For example, Congressman James Comer stated: “I am particularly glad to see
industrial hemp de-scheduled from the controlled substances list.” 164 Cong. Rec. H1014203, H10145 (emphasis added).
34. Daniel Mudd, You Down with CBD? Yea You Know Me—States Look to Incentivize
and Tax Growing Hemp Industry, J. MULTISTATE TAX'N & INCENTIVES 32, 32, (2019) (“[A]
variety of ‘industrial hemp’ products are being manufactured throughout the country from
hemp fibers (e.g., fabric, apparel, insulation, flooring, paper, plastics, rope, car parts, building

2022]

CANNABIS DERIVATIVES

183

of the Farm Bill, over half a million acres were licensed for hemp production and the
market was flooded with a variety of hemp products, ranging from textiles to
cosmetics.35 But as will be seen, this legislation had significantly broader influence
on the cannabis industry.
B. Cannabidiol (CBD)
For many years, entrepreneurs have tested the legal bounds and market for
cannabis variations. As an example, a 1972 U.S. Patent described production of
synthetic marijuana (i.e., synthetic delta-9 tetrahydrocannabinol), which has since
been marketed as Marinol.36 The DEA presently regulates the drug as a Schedule III
controlled substance37 with uses for appetite stimulation and the treatment of
chemotherapy-related vomiting.38 While that is an early instance of experimentation
in the cannabis market, current entrepreneurs follow in this trend by experimenting
with new products whose regulation under existing laws is uncertain.39 Cannabidiol
(CBD) is one such product.
CBD is a chemical found in the cannabis plant that—unlike delta-9
tetrahydrocannabinol—does not elicit a psychoactive response.40 Advocates assert
that the drug has a variety of health benefits, including the treatment of pain and
nausea.41 To this end, firms sell CBD in a variety of products, such as foods,

materials, etc.).”)
35. Hemp Indus. Ass’n v. United States Drug Enf't Admin., 539 F. Supp. 3d 120, 124
(D.D.C. 2021).
36. Unimed, Inc. v. Quigg, 888 F.2d 826, 827 (Fed. Cir. 1989) (citing U.S. Patent No.
3,668,224); U.S. FOOD & DRUG ADMIN., MARINOL® (DRONABINOL) CAPSULES 3 (2004),
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018651s021lbl.pdf
[https://perma.cc/B38N-8F5N] (“Dronabinol, the active ingredient in MARINOL® Capsules,
is synthetic delta-9- tetrahydrocannabinol (delta-9-THC). Delta-9-tetrahydrocannabinol is
also a naturally occurring component of Cannabis sativa L. (Marijuana).”).
37. Controlled Substances: Alphabetical Order, supra note 24 (with DEA number 7369
covering “Dronabinol (synthetic) in sesame oil in soft gelatin capsule as approved by FDA”).
38. U.S. FOOD & DRUG ADMIN., MARINOL® (DRONABINOL) CAPSULES 5–6 (2004),
supra note 36.
39. See Austin Bernstein & Christopher Smith, Challenges Ahead: Market Evolution,
Research, Intrastate Market Stability, and Hemp—Market, Business, and Consumer
Evolution, in CANNABIS LAW DESKBOOK § 2:21 (2021–2022 ed.) (“The development of new
cannabinoids and synthetic cannabinoids (Delta-8) is a prime example of how an
entrepreneurial market struggles to fit neatly into a tight regulatory box.”).
40. Gregory L. Gerdeman, Science is indisputable: Marijuana is Medicine, TAMPA BAY
TIMES (Apr. 8, 2014) https://www.tampabay.com/opinion/columns/column-science-isindisputable-marijuana-is-medicine/2174111/ [https://perma.cc/A25P-95ZL]. Indeed, CBD
actually moderates the influence of cannabis’ psychoactive agents. Thomas A. Duppong,
Industrial Hemp: How the Classification of Industrial Hemp as Marijuana Under the
Controlled Substances Act Has Caused the Dream of Growing Industrial Hemp in North
Dakota to Go Up in Smoke, 85 N.D. L. REV. 403, 408 (2009).
41. Andrew L. Scherf, The Societal and Economic Impacts of Recent Dramatic Shifts in
State Marijuana Law: How Should Minnesota Proceed in the Future?, 36 HAMLINE J. PUB. L.
& POL'Y 119, 140 (2015).
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shampoos, protein powders, and dog treats.42 While CBD can now be legally
produced (leading to multi-billion dollar market expectations),43 its treatment under
the Controlled Substances Act has fluctuated over the past decade.
Prior to the passage of the 2018 Farm Bill, the DEA viewed all CBD as a Schedule
I drug.44 Despite not eliciting a “high,” CBD could not be produced without
cultivating the cannabis plant, which is a violation of federal law.45 This changed
with the Farm Bill’s recognition that hemp (low delta-9 tetrahydrocannabinol) and
its extracts are legal.46 Given that CBD is plentiful in legal hemp, entrepreneurs could
now extract and sell legal CBD from hemp.47 This does not, however, mean that all
CBD and means of producing CBD are legal.
The manner through which the chemical is produced is legally significant.
Products derived from Schedule I cannabis (including CBD) remain illegal, because
“Marihuana Extract[s]” are expressly held to be Schedule I drugs.48 In contrast,

42. Alex Malyshev & Ted McDonough, The Marketing and Sale of Products Containing
Hemp and CBD Over the Internet, 23 J. INTERNET L. 1, 21 (2019). CBD occurring in cannabis
can be extracted as CBD oil. Ryan Marcus, Medicare, Medicaid, and Medical Marijuana:
Why Hospitals Should Not Be High on Patient Certification, 24 ANNALS HEALTH L. ADVANCE
DIRECTIVE 1, 3 (2014); Scherf, supra note 41, at 140. This oil can then be put into supplements
or food. See Letter from Cynthia Schnedar, U.S. Food & Drug Admin., to Natural Organic
Solutions (Feb. 26, 2015), https://web.archive.org/web/20190424055638/http://www.fda.gov/
ICECI/EnforcementActions/WarningLetters/2015/ucm436066.htm [https://perma.cc/JV5YDY7W]; Marijuana Gives Hope to Parents of Brain-Damaged Baby, ABC 7 (Apr. 5, 2016),
http://abc7chicago.com/health/parents-of-brain-damaged-baby-find-hope-inmarijuana/1275367/ [https://perma.cc/QM92-PFFB].
43. Jared West, Nebraska Nonsense: Trojan Horse or Cash Crop?, 99 NEB. L. REV. 509,
515–16 (2020) (“In the U.S., some estimate the market for CBD is expected to reach $20
billion in the next five years.”).
44. Establishment of a New Drug Code for Marihuana Extract, 81 Fed. Reg. 90194,
90194–96 (Dec. 14, 2016) (CBD extracts “fall within the new drug code 7350,” which is a
Schedule I drug); 21 CFR § 1308.11 (2016); Press Release, DEA, DEA Eases Requirements
for
FDA-Approved
Clinical
Trials
on
Cannabidiol
(Dec.
23,
2015),
https://www.dea.gov/press-releases/2015/12/23/dea-eases-requirements-fda-approvedclinical-trials-cannabidiol [https://perma.cc/6QPQ-RLKT] (“CBD is a Schedule I controlled
substance as defined under the CSA.”); Cannabidiol: Barriers to Research and Potential
Medial Benefits: Hearing Before the Caucus on International Narcotics Control, 114th Cong.
(2015) (statement of Joseph T. Rannazzisi, Deputy Assistant Drug Enforcement
Administration) (CBD is a Schedule I drug.).
45. There was some argument that CBD could be cultivated from legal hemp stalks. See
21 U.S.C. § 802(16) (2012) (exempting stalks from illegal cannabis). However, these
assertions were dubious with regard to whether the feat could be accomplished and whether
the resultant CBD would be legal. See W. Michael Schuster & Jack Wroldsen,
Entrepreneurship and Legal Uncertainty: Unexpected Federal Trademark Registrations for
Marijuana Derivatives, 55 AM. BUS. L.J. 117, 154–56 (2018).
46. Agriculture Improvement Act of 2018, Pub. L. No. 115-334, 132 Stat. 4490, 5018
(2018).
47. See GenCanna Glob. USA, Inc. v. Jenco Indus. Sales & Servs., LLC, No. 5:19-387,
2020 WL 94512, at *1 (E.D. Ky. Jan. 8, 2020) (discussing “the business of extracting and
distilling legal, non-intoxicating cannabidiol (‘CBD’) from industrial hemp.”).
48. Establishment of a New Drug Code for Marihuana Extract, 81 Fed. Reg. 90194,
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products derived from hemp (as described in the Farm Bill) are legal.49 This
conclusion relies on the Farm Bill’s statement that hemp and “all derivatives,
extracts, cannabinoids, [and] isomers” fall outside the scope of the Controlled
Substances Act.50 CBD’s status as contraband or legitimate product is thus path
dependent; the manner of production determines the product’s legality. This path
dependency is likewise important to issues surrounding a more recent entrant into
the cannabis market: Δ8-THC.
C. Delta-8 THC
As discussed above, delta-9 tetrahydrocannabinol is the primary psychoactive
agent in cannabis.51 However, a market has arisen for a different chemical found in
the cannabis plant: delta-8 tetrahydrocannabinol (Δ8-THC).52 This variant has the
same chemical formula as the more common delta-9 variety,53 but one carbon-carbon
double bond is located at a different place in its structure.54 Chemical variation of
this nature (called isomerization)55 can—as discussed below—bear legal and
pharmacological significance.56

90194–95 (Dec. 14, 2016) (“[A]n extract that contained only CBD . . . would fall within the
new drug code 7350.”); Controlled Substances: Alphabetical Order, supra note 24 (with DEA
Number 7350 covering “Marihuana Extract” as a Schedule I drug); see Wunderwerks, Inc. v.
Dual Beverage Co., No. 21-CV-04980, 2021 WL 5771138, at *3 (N.D. Cal. Dec. 6, 2021)
(citing 21 U.S.C. § 812(c)(10) and 21 CFR § 1308.11) (“Marijuana and derived substances .
. . are designated as Schedule I drugs.”) (emphasis added).
49. In re Stanley Bros. Soc. Enters., LLC, No. 86568478, 2020 WL 3288093, at *6
(T.T.A.B. June 16, 2020) (CBD derived from hemp “falls outside the CSA”); Examination
Guide 1-19: Examination of Marks for Cannabis and Cannabis-Related Goods and Services
After Enactment of the 2018 Farm Bill, USPTO (May 2, 2019), https://www.uspto.gov/
sites/default/files/documents/Exam%20Guide%201-19.pdf [https://perma.cc/Y8N7-D7UM]
(“Cannabis and CBD derived from marijuana (i.e., Cannabis sativa L. with more than 0.3%
THC on a dry-weight basis) still violate federal law[, but] those “derived from ‘hemp’ as
defined in the 2018 Farm Bill [are legal under the CSA in the eyes of the USPTO.]”).
50. 7 U.S.C.A. § 1639o (West).
51. Leas, supra note 3; Danovitch, supra note 9. There are eighty-five or more active
chemicals in cannabis, including Δ9-THC. Cressey, supra note 11.
52. Farah, supra note 15; see Green Trading Co. v. Shy, No. 1:20-CV-01787, 2021 WL
3135944, at *2 (D. Or. June 16, 2021), report and recommendation adopted, No. 1:20-CV01787, 2021 WL 3131309 (D. Or. July 14, 2021) (describing expected sales of Δ8-THC).
53. McWilliams, Goff & Williams, supra note 2 (“There are more than 100 cannabinoids
in cannabis, of which THC and CBD are only the most well-known.”).
54. Leas, supra note 3 (“Delta-8-THC is nearly identical in chemical structure to delta-9THC, differing only by the location of a carbon–carbon double bond.”); Farah, supra note 15
(“The main difference between Delta-8 and Delta-9 comes down to the location of a specific
bond between two of the atoms that make up each THC molecule.”); McWilliams, Goff &
Williams, supra note 2 (“[Delta-8 THC] differs from delta-9 THC by having one difference
in placement of a double carbon bond.”).
55. Isomers have the same number of the same atoms, but in different arrangements.
RALPH H. PETRUCCI, WILLIAM S. HARWOOD & F. GEOFFREY HERRING, GENERAL CHEMISTRY:
PRINCIPLES AND MODERN APPLICATIONS 91 (8th ed. 2022).
56. See McWilliams, Goff & Williams, supra note 2 (discussing non-psychoactive CBD
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Similar to delta-9, Δ8-THC produces psychotropic effects (a “high”), but at a
reduced level.57 Users report that Δ8-THC is less likely to cause anxiety or sedation
and leaves them more clear-headed relative to common cannabis variants.58 Perhaps
unsurprisingly, Δ8-THC has become a significant industry, as evidenced by recent
testimony describing over $12.5 million dollars in damages arising from Δ8-THC
losses.59 Similarly, another firm reported nine-month revenues exceeding $60
million for Δ8-THC vaping products.60 Despite this success, legal questions surround
the drug.
Δ8-THC is expressly named as a Schedule I drug under the Controlled Substances
Act.61 There are, however, strong arguments that the 2018 Farm Bill legalized Δ8THC derived from legal hemp—just as that statute legalized CBD derived from
hemp.62 Recall the Farm Bill’s mandate that “derivatives [and] extracts” from legal
hemp are beyond the Controlled Substances Act’s reach.63 Further, while that statute
specifically defined legal hemp with regard to its low “delta-9 tetrahydrocannabinol
concentration,” it placed no limitations on Δ8-THC concentrations.64 Consistent with
this understanding, certain government entities believe that Δ8-THC extracted from
hemp is legal.65
However, a comprehensive analysis requires recognition that the analogy to CBD
produced from hemp may be imperfect. CBD occurs at relatively high concentrations
within hemp, and thus, it can be efficiently extracted and concentrated to produce

and its psychoactive isomer, Δ8-THC); see also Gerdeman, supra note 40 (stating CBD is not
psychoactive); United States v. Wright, 515 F. Supp. 3d 277, 282 (M.D. Pa. 2021) (discussing
the importance of isomers with regard to controlled substances).
57. Leas, supra note 3; ALISON MACK & JANET JOY, MARIJUANA AS MEDICINE?: THE
SCIENCE BEYOND THE CONTROVERSY 99 (2000) (“Delta-8-THC is a less potent variant of delta9-THC, the primary psychoactive ingredient in marijuana.”). But see Carolynn Conron,
Canada's Marijuana Medical Access Regulations: Up in Smoke, 6 ALB. GOV'T L. REV. 259,
295 (2013) (“Unlike Delta-9-THC, Delta-8-THC is not psychoactive.”) (emphasis added); see
also MITCH EARLEYWINE, UNDERSTANDING MARIJUANA: A NEW LOOK AT THE SCIENTIFIC
EVIDENCE 180 (2002).
58. Farah, supra note 15 (“People report [Delta-8] as being less anxiety-provoking, less
sedating and a little more clear-headed than THC.”). Further, early evidence suggests distinct
medical applications compared to delta-9. Leas, supra note 3 (“The pharmacological profile
of delta-8-THC also suggests it has antiemetic, anxiolytic, appetite-stimulating, analgesic, and
neuroprotective properties, indicating that it may have therapeutic applications and that some
of these applications may differ from delta-9-THC.”).
59. Green Trading Co., 2021 WL 3135944 at *2 (describing turning 274,000 pounds of
hemp into 4,566.7 liters of Δ8-THC, with a value of $12,786,666.60).
60. AK Futures LLC, 35 F.4th at 686.
61. Controlled Substances: Alphabetical Order, supra note 24.
62. See supra notes 4–5 and accompanying text.
63. 7 U.S.C.A. § 1639o (West).
64. Id. (showing no mention of Δ8-THC); AK Futures LLC, 35 F.4th at 690 (“[T]he only
statutory metric for distinguishing controlled marijuana from legal hemp is the delta-9 THC
concentration level.”).
65. See Letter from Terrence L. Boos, Drug Enf’t Amin., to Donna C Yeatman, Ala. Bd.
of Pharmacy (Sept. 15, 2021), https://albop.com/oodoardu/2021/10/ALBOP-synthetic-delta8THC-21-7520-signed.pdf [https://perma.cc/8L95-UCMU].
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CBD goods.66 In contrast, Δ8-THC occurs naturally in hemp, but in much lower
amounts.67 Thus, while it is possible to extract it from the cannabis plant, many
commenters assert that it is not currently feasible to extract Δ8-THC in economically
viable quantities.68 In reality, the drug is commonly produced by taking CBD
extracted from legal hemp and chemically altering it to create Δ8-THC.69
The relevant question thus becomes: does the Controlled Substances Act regulate
Δ8-THC that is produced through a chemical reaction starting with CBD extracted
from legal hemp? Recalling that the Farm Bill legalized “derivatives [and] extracts”
from hemp,70 the issue is simplified to whether Δ8-THC produced in this manner
constitutes hemp “derivatives [or] extracts.” A thorough analysis of the DEA’s
stance on this issue clarifies that this sort of Δ8-THC is a derivative of legal hemp
and therefore, is legal itself.71
In September of 2021, the DEA issued instructions on the interaction of the 2018
Farm Bill, legal hemp, and Δ8-THC.72 It stated that Δ8-THC “in or derived from the
cannabis plant” is not subject to the federal regulation.73 The use of the phrase “in or
derived from” is important. Per basic canons of construction, the choice to use two
different terms indicates two different meanings are conveyed.74
The term “in” clarifies that Δ8-THC molecules extracted from legal hemp are
legal (similar to the extraction of CBD molecules found in hemp). Further, the phrase
“derived from the cannabis plant” clarifies that Δ8-THC molecules created from

66. See Britt E. Erickson, Delta-8-THC Craze Concerns Chemists: Unidentified ByProducts and Lack of Regulatory Oversight Spell Trouble for Cannabis Products Synthesized
from CBD, CHEM. & ENG’G NEWS (Aug. 30, 2021), https://cen.acs.org/biologicalchemistry/natural-products/Delta-8-THC-craze-concerns/99/i31
[https://perma.cc/MD72Z935] (describing “an oversupply of CBD extracted from US-grown hemp”); see also
Hempchain Farms, LLC v. Sack, 516 F. Supp. 3d 197, 201 (N.D.N.Y. 2021) (describing
cannabis strains with “high CBD and low THC content”).
67. Leas, supra note 3; McWilliams, Goff & Williams supra note 2 (“Delta-8 THC, as
opposed to Delta-9 THC, is a cannabinoid usually found in very trace amounts in cannabis
plants.”).
68. See Erickson, supra note 66.
69. Leas, supra note 3 (“Because CBD isomers are similar in structure to THC isomers,
they can be converted to THC isomers through a relatively simple series of chemical
reactions.”).
70. 7 U.S.C.A. § 1639o (West).
71. See Letter from Terrence L. Boos to Donna C. Yeatman, supra note 65.
72. Id.
73. Id.
74. United States v. Bean, 537 U.S. 71, 76 n.4 (2002) (“The use of different terms within
related statutes generally implies that different meanings were intended.”) (quoting 2A N.
Singer, Sutherland on Statutes and Statutory Construction § 46:06, p. 194 (6th ed. 2000);
Conway v. United States, 997 F.3d 1198, 1204 (Fed. Cir. 2021) (“[T]he use of different terms
signals the General Assembly's intent to afford those terms different meanings.”) (quoting Bd.
of City Comm'rs of the Cnty. of Teller v. City of Woodland Park, 333 P.3d 55, 58 (Colo.
2014); Bank of N.Y. v. FDIC., 453 F. Supp. 2d 82, 93–94 (D.D.C. 2006), aff'd, 508 F.3d 1
(D.C. Cir. 2007) (“When ‘different terms are used in a single piece of legislation, [a] court
must presume that Congress intended the terms to have different meanings.’”) (quoting
Transbrasil S.A. Linhas Aereas v. Dep’t. of Transp., 791 F.2d 202, 205 (D.C. Cir. 1986).
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cannabis plant base materials (i.e., CBD extracted from hemp) are likewise
acceptable. Indeed, this interpretation is further supported by contrasting it with the
DEA’s contemporaneous position that Δ8-THC “produced synthetically from noncannabis materials” is a Schedule I drug.75 As used there, the words “non-cannabis
materials” would be superfluous, unless the DEA was opining that Δ8-THC
produced from cannabis materials is legal. Such a reading would be improper, as
courts presume interpretations that render language superfluous to be incorrect.76
The courts have reached a similar conclusion. Indeed, one federal litigant
specifically argued that Δ8-THC derived from hemp via a “chemical process” was
subject to the Controlled Substances Act because it was “synthetically derived,” as
opposed to non-synthetic Δ8-THC that comes from hemp.77 The district court
rejected this position. That court stated on the record at the preliminary injunction
stage that it believed “hemp-derived” Δ8-THC is legal.78
The Ninth Circuit affirmed this finding. In doing so, it emphasized that while a
chemical process may be used to extract Δ8-THC from hemp, this does not render
the Δ8-THC illegal.79 To support this proposition, it cited the definition of legal
hemp, which includes “derivatives [and] extracts” that have a “delta-9
tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight

75. See Letter from Terrence L. Boos to Donna C. Yeatman, supra note 65 (emphasis
added). Indeed, the federal government has shown a willingness to pursue criminal charges
against those who produce synthetic drugs that mimic the effects of THC and cannabis.
Synthetic Drug Sales Send a Mother and Her Son to Federal Prison, U.S. DEP’T OF JUST. (Mar.
2, 2015), https://www.justice.gov/usao-ndia/pr/synthetic-drug-sales-send-mother-and-herson-federal-prison [https://perma.cc/8E66-6LFK] (“A mother and her son who were convicted
of selling synthetic cannabinoids . . . from two eastern Iowa businesses were sentenced today
in federal court in Cedar Rapids.”).
76. Fed. Express Corp. v. U.S. Dep't of Com., 486 F. Supp. 3d 69, 82 (D.D.C. 2020)
(“[T]here is an interpretive ‘presumption that statutory language is not superfluous.’”)
(quoting McDonnell v. United States, 579 U.S. 550, 569 (2016)); Star-Glo Assocs. v. United
States, 59 Fed. Cl. 724, 730 (2004), aff’d on other grounds, 414 F.3d 1349 (Fed. Cir. 2005)
(“[T]he court must avoid an interpretation of a clause or word which renders other provisions
of the statute inconsistent, meaningless, or superfluous.”).
77. Memorandum in Opposition to Motion for Preliminary Injunction at 7–8, AK Futures
LLC v. Boyd St. Distro, LLC, No. 8:21-cv-01027, 2021 WL 4860513 (C.D. Cal, Aug. 6, 2021)
(No. 24, at 7–8) (citing Interim Final Rule, Aug. 21, 2020) (to be codified at 21 C.F.R. pts.
1308, 1312), https://www.deadiversion.usdoj.gov/fed_regs/rules/2020/fr0821.htm [https://
perma.cc/JRE8-NF2H].
78. Minute Order [In Chambers] Amended Order Regarding Motion for Preliminary
Injunction, AK Futures LLC v. Boyd St. Distro, LLC, No. 8:21-cv-01027, 2021 WL 4860513:
Plaintiff AK Futures LLC (“Futures”) moved for a preliminary injunction, ECF No. 29, at 9
(C.D. Cal., Sept. 9, 2021) (citing Notice of Motion and Motion for Preliminary Injunction re
per FRCP 65 and for Leave to Immediately Commence Discovery filed by Plaintiff AK
Futures LLC, ECF. No. 15, at Exhibit 11 Declaration of James Clelland, ¶¶ 2–3) (stating that
“Delta–8 is a hemp-derived product with less than 0.3% of the psychoactive delta-9tetrahydrocannabinol compound and is permitted to be sold in interstate commerce under the
2018 Farm Bill.”).
79. AK Futures LLC, 35 F.4th at 692. This mimics the DEA’s position that “Δ8-THC
synthetically produced from non-cannabis materials is controlled under the CSA as a
“tetrahydrocannabinol.” Letter from Terrence L. Boos to Donna C. Yeatman, supra note 65.
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basis.”80 The Court closed by opining that a contrary opinion was not possible—
noting that the statute is “unambiguous and precludes a distinction based on
manufacturing method.”81
While the DEA and the Ninth Circuit have stated their positions regarding Δ8THC, other federal agencies take a different view on the drug’s legality.82 Further
complicating the legal uncertainty in the cannabis and Δ8-THC market is the constant
state of flux surrounding its regulation.83 A common source of this uncertainty and
variation is state-level cannabis laws and their interaction with federal statutes.
D. State Regulation
To this point, we have exclusively addressed federal law and cannabis. However,
significant state regulation has occurred in parallel with national mandates. The
recent trend at the state level is toward cannabis deregulation.84 Moves of this nature
include medical use regimes,85 decriminalization,86 and legalization.87 Indeed, since
California approved cannabis for medical use in 1996,88 over thirty-five states have
introduced a medical-use system, and a number of those allow for recreational use
as well.89 This movement is consistent with evolving public opinion. Support for

80. 7 U.S.C. § 1639o(1); AK Futures LLC, 35 F.4th at 692.
81. AK Futures LLC, 35 F.4th at 692.
82. See, e.g., U.S. Trademark Application Serial No. 90,036,541, Office Action (dated
Oct. 21, 2021) (USPTO trademark examiner stating that Δ8-THC is illegal); U.S. Trademark
Application Serial No. 90,289,354, Office Action (dated Oct. 18, 2021) (same); U.S.
Trademark Application Serial No. 90,251,954, Office Action (dated Aug. 4, 2021) (same);
U.S. Trademark Application Serial No. 90,160,477, Office Action (dated Aug. 4, 2021)
(same).
83. Mike Schuster & Robert Bird, Legal Strategy During Legal Uncertainty: The Case of
Cannabis Regulation, 26 STAN. J.L. BUS. & FIN. 362, 371–78 (2021) (describing different
types of uncertainty in the cannabis industry).
84. Lauren Males, Current Trends in Marijuana Regulation, 6 HOUS. L. REV. 185 (2016);
John T. Holden, Christopher M. Mcleod & Marc Edelman, Regulatory Categorization and
Arbitrage: How Daily Fantasy Sports Companies Navigated Regulatory Categories Before
and After Legalized Gambling, 57 AM. BUS. L.J. 113, 116 n.16 (2020) (“[S]tates and the
federal government remain at odds over the sale of both medical and recreational marijuana.”).
85. Some evidence exists supporting cannabis as a treatment for “nausea and vomiting,
anorexia and wasting, neuropathic pain and muscle spasticity.” Danovitch, supra note 9, at
94.
86. See, e.g., German Lopez, North Dakota Quietly Decriminalized Marijuana, VOX
(May 10, 2019), https://www.vox.com/policy-and-politics/2019/5/10/18563776/northdakota-marijuana-decriminalization-legalization [https://perma.cc/QWZ9-QH8V].
87. See, e.g., Love v. Pa. Bd. of Prob. & Parole, No. 149 C.D. 2015, 2015 WL 8145191,
at *3 n.12 (Pa. Commw. Ct. Dec. 3, 2015); Males, supra note 84, at 186.
88. CAL. HEALTH & SAFETY CODE § 11362.5 (West 1996).
89. State Medical Cannabis Laws, NAT’L CONF. STATE LEGISLATURES (Sept. 12, 2022),
https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx [https://perma.cc/
74TZ-35JA] (“As of February 2, 2022, 37 states and three territories allow for the medical use
of cannabis products . . . As of May 27, 2022, 19 states, two territories and the District of
Columbia have enacted measures to regulate cannabis for adult non medical use.”); In re
Hinton, No. 8566301 (T.T.A.B. Sept. 28, 2015); United States v. French, No. 1:12-cr-00160,
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cannabis legalization was just above 10% in 1970.90 Approximately fifty years later,
over 90% of the population believe that cannabis should be legal in some form
(medical or recreational).91
Despite these moves toward relaxation of cannabis regulation within the states,
the drug remains (in large part)92 illegal at the federal level.93 Neither state
legislatures nor state referendums have the capacity to change this.94 Indeed, the
President retains a significant amount of discretion regarding whether the federal
government will enforce its cannabis prohibitions (e.g., the Controlled Substances
Act) in states where it is legal.95 As an example, one can compare President Obama’s
largely hands-off approach to cannabis enforcement in states with their own cannabis

2015 WL 1925592, at *2 (D. Me. Apr. 28, 2015); Raich v. Gonzales, 500 F.3d 850, 865 (9th
Cir. 2007). Many jurisdictions have decriminalized cannabis to some extent. See, e.g., MASS.
GEN. LAWS ANN. ch. 94C, § 32L (West 2017); State v. Gradt, 366 P.3d 462 (Wash. Ct. App.
2016). “[In] January 2014, Colorado became the first state to legalize recreational marijuana.”
Kathryn Kisska-Schulze & Adam Epstein, “Show Me the Money!”– Analyzing the Potential
State Tax Implications of Paying Student-Athletes, 14 VA. SPORTS & ENT. L.J. 13, 28 (2014).
90. Patrick A. Tighe, Note, Underbanked: Cooperative Banking as a Potential Solution
to the Marijuana-Banking Problem, 114 MICH. L. REV. 803, 806 (2016); Marc Fisher &
Richard Johnson, A Brief History of Public Opinion on Marijuana Legalization, WASH. POST
(Feb. 21, 2014), http://www.washingtonpost.com/local/a-brief-history-of-public-opinion-onmarijuana-legalization/2014/02/21/77c04e40-9b4a-11e3-975d-107dfef7b668_graphic.html
[https://perma.cc/SG83-SDSE].
91. Ted Van Green, Americans Overwhelmingly Say Marijuana Should Be Legal for
(Apr. 16, 2021),
Recreational or Medical Use, PEW RSCH. CTR.
https://www.pewresearch.org/fact-tank/2021/04/16/americans-overwhelmingly-saymarijuana-should-be-legal-for-recreational-or-medical-use/ [https://perma.cc/5TMH-3DJG]
(“[A]n overwhelming share of U.S. adults (91%) say either that marijuana should be legal for
medical and recreational use (60%) or that it should be legal for medical use only (31%).
Fewer than one-in-ten (8%) say marijuana should not be legal for use by adults.”).
92. See supra text accompanying Sections 0.0–0.
93. United States v. Filippi, 622 F. App’x 25, 26 (2d Cir. 2015).
94. See, e.g., Sacramento Nonprofit Collective v. Holder, 552 F. App’x 680, 682–83 (9th
Cir. 2014).
95. Barack Obama, President of the United States, Remarks by the President in a Youth
Town Hall, at *11 (Oct. 14, 2010) (2010 WL 4019651). The Obama administration would still
actively enforce these laws to achieve goals such as preventing children from accessing the
drug and hindering organized crime. Memorandum from James M. Cole, Deputy Att’y Gen.
to all U.S. Att’ys (Aug. 29, 2013), https://www.justice.gov/iso/opa/resources/
3052013829132756857467.pdf [https://perma.cc/E8QM-AJ9R]. Of course, these policies did
not change the Schedule I nature of the drug. In re JJ206, LLC, 120 U.S.P.Q.2d (BNA) 1568,
1570 (T.T.A.B. 2016). It is notably possible for Congress to withhold funds for cannabis
enforcement in certain situations, which would preclude enforcement by the federal executive.
See Tom Angell, Congress Votes to Block Feds from Enforcing Marijuana Laws in Legal
States, FORBES (June 20, 2019), https://www.forbes.com/sites/tomangell/2019/06/20/
congress-votes-to-block-feds-from-enforcing-marijuana-laws-in-legal-states/?sh=3e7e9bae4
b62 [https://perma.cc/X86Q-X6BA].
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regulations96 with President G.W. Bush’s strong enforcement policies.97
Accordingly, while the federal executive has the power to enforce federal regulation
in states where it is legal, it is uncertain exactly if and when it will do so.
The federal Congress has, however, recognized the states’ ability to diverge from
federal policy in limited circumstances. The (federal) 2018 Farm Bill specifically
stated that “no preemption” was intended with regard to the states’ ability to further
regulate industrial hemp.98 In such a regulatory environment, states have the ability
to criminalize hemp and it derivatives, even if it is legal at the federal level.99
Consistent with this power, North Dakota has expressly banned chemical alteration
of compounds found in cannabis “to create isomers of [THC], including delta-8,
delta-9, and delta-10.”100 At present, at least eighteen states have restricted Δ8-THC
in some manner.101
This patchwork set of state regulations has only increased questions about the
legality of Δ8-THC102 (and cannabis generally).103 As explored in prior scholarship,
uncertainty of this nature can present value to certain businesspeople.104 This Article
addresses this theme as it applies to the Δ8-THC space in Part III, but first, the stage
must be set with a discussion of our second relevant area of the law: trademarks.

96. See Kevin J. Fandl, Presidential Power to Protect Dreamers: Abusive or Proper?, 36
YALE L. & POL’Y REV. INTER ALIA 1, 10 (2018).
97. See Bradley E. Markano, Enabling State Deregulation of Marijuana Through
Executive Branch Nonenforcement, 90 N.Y.U. L. REV. 289, 316–17 (2015).
98. 7 U.S.C.A. § 1639p (“Nothing in this subsection preempts or limits any law of a State
or Indian tribe that-- (i) regulates the production of hemp; and (ii) is more stringent than this
subchapter.”).
99. Farm Bill to Allow States, Tribes to Regulate Hemp Production, in 47 CONTROLLED
SUBSTANCES HANDBOOK NEWSL. 8 (2019) (“Each state has controlled substance laws, which
are not preempted by the CSA, and the current legislation would allow them to develop hemp
production requirements more stringent than those set out in the bill.”); see also supra notes
49–50, 65–73 and accompanying text.
100. N.D. CENT. CODE ANN. § 4.1–18.1 (West 2021); see also LA. STAT. ANN. § 3:1482
(2021) (prohibiting the sale of “[a]ny consumable hemp product without a license or permit.”).
101. Alex Malyshev & Sarah Ganley, Controlling Cannabis and the Classification of
Delta-8 THC, REUTERS (Sept. 22, 2021), https://www.reuters.com/legal/litigation/controllingcannabis-classification-delta-8-thc-2021-09-22/ [https://perma.cc/7SDK-A4GX] (“As of
August 2021, at least 18 states have restricted or banned Delta-8 THC in some way, including:
Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, Kentucky, Idaho, Iowa,
Michigan, Mississippi, Montana, New York, North Dakota, Rhode Island, Utah, Vermont, and
Washington.”).
102. See, e.g., Sanford Nowlin, Delta-8 Retailers and Users Struggle Through an
Uncertain Regulatory Environment, SAN ANTONIO CURRENT (Oct. 21, 2021),
https://www.sacurrent.com/sanantonio/delta-8-retailers-and-users-struggle-through-anuncertain-regulatory-environment/Content?oid=27375311 [https://perma.cc/QXQ6-453Q]
(“[L]egal experts warn that [Δ8-THC] isn’t so much legal in Texas as it is operating in an
uncertain and unregulated space.”).
103. Schuster & Bird, supra note 83, at 371–78 (discussing the uncertainty surrounding
cannabis regulation).
104. Schuster & Wroldsen, supra note 45, at 118.
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E. Trademark Law
The trademark system is intended to prevent multiple parties from using
trademarks that are likely to cause consumer confusion.105 Relevant considerations
when analyzing the potential for confusion include the type of products or services
being sold, the geographic scope of use, and the marks’ similarity.106 Through this
regime, consumers should be able to efficiently distinguish what company provides
which product when making purchasing decisions.107 The ability to differentiate a
firm’s goods from those of its competitors encourages the creation of high-quality
wares, under the theory that this investment will ultimately increase sales.108 Indeed,
in some industries, a firm’s trademark may be its most important asset.109
1. Federal Protection
Rights in a trademark are created through use in commerce.110 Once a firm
establishes rights by using the mark to identify the firm, it can seek federal
registration with the USPTO.111 While not necessary to own a trademark, federal
registration provides significant benefits to registrants beyond those available to nonregistrants.112 In important part for the current discussion, federal registration creates
nationwide constructive use of the mark.113 This allows the owner to prevent
subsequent adoption of a confusingly similar mark anywhere in the United States,
regardless of the actual geographical scope of use.114 Other firms that were

105. Lois Sportswear, USA, Inc. v. Levi Strauss & Co., 799 F.2d 867, 871 (2d Cir. 1986)
106. Wiener King, Inc. v. Wiener King Corp., 407 F. Supp. 1274, 1280 (D.N.J. 1976),
rev’d on other grounds, 546 F.2d 421 (3d Cir. 1976); J. THOMAS MCCARTHY, MCCARTHY ON
TRADEMARKS AND UNFAIR COMPETITION § 19:108 (4th ed. 2017).
107. MCCARTHY, supra note 106, § 2:1; MARGRETH BARRETT, INTELLECTUAL PROPERTY:
CASES AND MATERIALS 702 (4th ed. 2011); CRAIG ALLEN NARD, MICHAEL J. MADISON &
MARK P. MCKENNA, THE LAW OF INTELLECTUAL PROPERTY 867–68 (4th ed. 2014).
108. In re Int'l Flavors & Fragrances, Inc., 183 F.3d 1361, 1367 (Fed. Cir. 1999);
MCCARTHY, supra note 106, § 2:4; BARRETT, supra note 107, at 702.
109. Kieran G. Doyle, Trademark Strategies for Emerging Marijuana Businesses, 21
WESTLAW J. OF INTELL. PROP. 1,2 (2014).
110. 15 U.S.C. § 1125 (2012).
111. Id. Applicants must show use in commerce or, for intent to use applicants, they must
show a bona fide intent to use in the future. 15 U.S.C. § 1051 (2021).
112. See, e.g., 15 U.S.C. § 1057(b) (presumption of validity); id. § 1065 (incontestability);
id. § 1117; id. § 1121; B & B Hardware, Inc. v. Hargis Indus., 575 U.S. 138, 142 (2015)
(“Registration is significant. The Lanham Act confers ‘important legal rights and benefits’ on
trademark owners who register their marks.”) (citation omitted); In re Brunetti, 877 F.3d 1330,
1344 (Fed. Cir. 2017), aff'd sub nom. Iancu v. Brunetti, 139 S. Ct. 2294 (2019) (describing
benefits).
113. 15 U.S.C. § 1057(c) (2012).
114. In re Beatrice Foods Co., 429 F.2d 466, 472 (C.C.P.A. 1970); Davidoff Extension
S.A. v. Davidoff Comercio E Industria Ltda., 747 F. Supp. 122, 128 (D.P.R. 1990);
MCCARTHY, supra note 106, § 23:109; NARD, MADISON & MCKENNA, supra note 107, at 980.
There are some limitations associated with this rule. See NARD, MADISON & MCKENNA, supra
note 107, at 980 (discussing certain “restrictions” on nationwide constructive use).
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previously using the mark can continue but may be limited in their ability to expand
where they use the mark.115
To secure registration, an application must satisfy a series of technical
requirements, including not being confusingly similar to an existing mark.116 Should
the trademark examiner identify a ground for refusal, this information will be
communicated to the applicant in a written “office action” to which responsive
arguments or amendments can be made.117 If the examiner identifies no issues or if
all problems are corrected, the application will be published for public review.118
Assuming no third party successfully establishes that registration is improper,119 the
mark will be registered with the USPTO.120
One requirement for registration is particularly relevant with regard to Δ8-THC
and cannabis trademarks: the applicant must show that it is using the mark in legal
commerce.121 More specifically, the use must be consistent with federal law.122 This
rule was established to avoid an “anomalous” position where one branch of the
federal government (e.g., the DEA) prohibits an act while the Trademark Office is
simultaneously granting protection for marks associated with the prohibited
behavior.123 The legal-use requirement is unimportant for most applicants, but as
fully discussed later, it can prove a significant hurdle for cannabis-related marks.124
2. State Protection
Federal trademark law exists in parallel with state-level systems125 with both
providing a similar set of rights.126 State protections can be created through common

115. Allard Enters., Inc. v. Advanced Programming Res., Inc., 249 F.3d 564, 572 (6th Cir.
2001); MCCARTHY, supra note 106, § 16:18; NARD, MADISON & MCKENNA , supra note 107,
at 980.
116. 15 U.S.C. § 1051–52 (2012); MCCARTHY, supra note 106, § 19:10; NARD, MADISON
& MCKENNA, supra note 107, at 1011.
117. TMEP § 1109.16(b).
118. 15 U.S.C. § 1062; 37 C.F.R. § 2.80 (2015).
119. 37 C.F.R. § 2.101 (2016).
120. 15 U.S.C. § 1051(d)(1) (2012). An intent to use application must establish use before
registration will occur. NARD, MADISON & MCKENNA, supra note 107, at 1011–12.
121. The Clorox Co. v. Armour-Dial, Inc., 214 U.S.P.Q. 850, 851 (T.T.A.B. 1982); Dessert
Beauty, Inc. v. Fox, 617 F. Supp. 2d 185, 189 (S.D.N.Y. 2007), aff'd, 329 F. App'x 333 (2d
Cir. 2009); 15 U.S.C. § 1051–2; MCCARTHY, supra note 106, § 16:18; NARD, MADISON &
MCKENNA, supra note 107, at 1011. A party that has a bona fide intent to begin using the mark
in the future may also submit a trademark application. Id. at 1011–12.
122. TMEP § 907 (“[Examiners] must inquire about compliance with federal laws or
refuse registration based on the absence of lawful use in commerce.”) (emphasis added).
123. CreAgri, Inc. v. USANA Health Scis., Inc., 474 F.3d 626, 630 (9th Cir. 2007). As a
second policy matter, the legal use requirement encourages parties to consider relevant law
before rushing to begin use in commerce. Id.
124. See infra Part 0.
125. MCCARTHY, supra note 106, §§ 16:18.50 n.1, 26.2; NARD, MADISON & MCKENNA,
supra note 107, at 867.
126. Value House v. Phillips Mercantile Co., 523 F.2d 424, 429 (10th Cir. 1975); GTE
Corp. v. Williams, 649 F. Supp. 164, 168 (D. Utah 1986), aff'd, 904 F.2d 536 (10th Cir. 1990)
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law, statute, or both, depending on the jurisdiction.127 Recognizing the existence of
this bifurcated system, a brief discussion of the state-level trademark system is
warranted to show why it is not an equal substitute for federal registration of Δ8THC marks.
Just like the federal regime, state rights accrue once a mark is used in
commerce,128 though the geographic scope of these rights varies. Common law state
trademark rights extend protection within the area that the mark is currently being
used129 or into the region where the use will naturally expand.130 Many state statutory
registration systems provide statewide rights,131 though this breadth of protection is
not uniform.132 Regardless of the state system, rights only accrue once a trademark
owner actually uses a mark in commerce in that state, and these laws will not create
rights outside of the jurisdiction.133
While federal registration will not supersede state-level rights established through
prior use,134 the geographic disparities are significant. Federal registration creates
rights in a trademark across the entire nation, except in areas where another has
already used the mark in commerce in a similar manner.135 Further, once a mark is
registered at the federal level, any prior state rights usually become frozen within the
actual scope of current geographic use.136 Thus, while state systems create some
rights, they can only provide nationwide protection after the firm engages in

(footnote and citations omitted).
127. Emerald City Mgmt., LLC v. Kahn, No. 4:14cv358, 2014 WL 3835826, at *3 (E.D.
Tex. June 19, 2014), report and recommendation adopted, No. 4:14-cv-358, 2014 WL
3809660 (E.D. Tex. Aug. 1, 2014), aff'd, 624 F. App'x 223 (5th Cir. 2015); S & S Invs., Inc.
v. Hooper Enterps., 862 P.2d 1252, 1254–55 (Ct. App. 1993); GTE Corp. v. Williams, 649 F.
Supp. 164, 168 (D. Utah 1986), aff'd, 904 F.2d 536 (10th Cir. 1990).
128. Steven J. Eisen & Anne J. Cheatham, Trademark and Marketing Issues for Financial
Institutions, 60 CONSUMER FIN. L.Q. REP. 194, 198–99 (2006).
129. NARD, MADISON & MCKENNA., supra note 107, at 980.
130. Popular Bank of Fla v. Banco Popular de Puerto Rico, 9 F. Supp. 2d 1347, 1355 (S.D.
Fla. 1998); Stat Ltd. v. Beard Head, Inc., 60 F. Supp. 3d 634, 639 (E.D. Va. 2014). The area
of normal expansion depends on the “size and rate of previous expansion, business activity,
advertising, and geographic proximity; accordingly, mere hope of expansion is insufficient to
establish such a zone.” Dan L. Burk, Trademark Doctrines for Global Electronic Commerce,
49 S.C. L. REV. 695, 707 (1998); Blue Ribbon Feed Co. v. Farmers Union Cent. Exch., 731
F.2d 415, 422 (7th Cir. 1984).
131. Lee Ann W. Lockridge, Abolishing State Trademark Registrations, 29 CARDOZO
ARTS & ENT. L.J. 597, 619–20 (2011); see, e.g., MASS. GEN. LAWS ANN. ch. 110H, § 5(b)
(West 2017); TEX. BUS. & COM. CODE ANN. § 16.15(b) (West 2017); Optimal Pets, Inc. v.
Nutri-Vet, LLC, 877 F. Supp. 2d 953, 958 (C.D. Cal. 2012).
132. Thrifty Rent-A-Car Sys., Inc. v. Thrift Cars, Inc., 639 F. Supp. 750, 756 (D. Mass.
1986), aff'd, 831 F.2d 1177 (1st Cir. 1987).
133. Eisen & Cheatham, supra note 128, at 198–99.
134. Dorpan, S.L. v. Hotel Meliá, Inc., 728 F.3d 55, 62 (1st Cir. 2013).
135. Allard Enterps., Inc. v. Advanced Programming Res., Inc., 249 F.3d 564, 572 (6th
Cir. 2001).
136. Tana v. Dantanna's, 611 F.3d 767, 780 (11th Cir. 2010); Allard Enterps., Inc., 249
F.3d at 572; but see Burk, supra note 130, at 709 (stating it is feasible “for a prior user that
files a tardy concurrent use application to preserve his common-law area of actual usage and
zone of natural expansion.”).
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commerce in all fifty states and navigates each jurisdiction’s legal system.
Unsurprisingly, firms prefer federal registration when it is available.137 This will be
a theme underlying the following discussions about trademark protection and Δ8THC.
II. THE USPTO AND CANNABIS-RELATED TRADEMARK APPLICATIONS
The USPTO generally refuses to register cannabis-related trademarks.138 This is
unsurprising, given its classification as a Schedule I drug under federal law.139 The
Trademark Office did, however, reevaluate this stance with regard to CBD marks
beginning around 2013.140 The first Section below describes the evolving approaches
to CBD applications, followed by a comparison to the current treatment of Δ8-THCrelated marks. Several issues with the current approach are raised, including strong
arguments regarding why this refusal appears to be both legally incorrect and
inconsistent with USPTO policy.
A. CBD Trademarks
While the Trademark Office has consistently refused registration for marijuana
goods,141 its treatment of cannabis derivatives has historically been less
predictable.142 On this point, CBD-related trademarks are instructive. As previously
discussed in Section I.0, CBD derived from hemp has been considered legal under
the Controlled Substances Act since the passage of the 2018 Farm Bill.143 Based on
this, CBD marks can now usually be registered.144 This was not always the case.

137. Patricia Kimball Fletcher, Joint Registration of Trademarks and the Economic Value
of a Trademark System, 36 U. MIAMI L. REV. 297, 298 n.7 (1982); Cynthia E. Kernick,
Protecting Your Intellectual Property: An Introduction, 53 PRAC. L. 49, 50 (2007) (“[F]ederal
[trademark] protection is generally preferable.”).
138. In re JJ206, LLC, 120 U.S.P.Q.2d (BNA) 1568, 1570 (T.T.A.B. 2016); In re Morgan
Brown, 119 U.S.P.Q.2d (BNA) 1350, 1351 (T.T.A.B. 2016); BBK Tobacco & Foods LLP v.
Skunk Inc., No. CV-18-02332, 2020 WL 1285837, at *3 (D. Ariz. Mar. 18, 2020).
139. Controlled Substances: Alphabetical Order, supra note 24; Examination Guide 1-19:
Examination of Marks for Cannabis and Cannabis-Related Goods and Services after
Enactment of the 2018 Farm Bill, supra note 49 (“[T]he USPTO will continue to refuse
registration when the identified services in an application involve cannabis that meets the
definition of marijuana and encompass activities prohibited under the CSA because such
services still violate federal law.”).
140. The first CBD-related mark identified by the author was U.S. Trademark Application
Serial No. 86,099,419 (filed Oct. 23, 2013).
141. In re JJ206, LLC, 120 U.S.P.Q.2d (BNA) at *2; In re Morgan Brown, 119 U.S.P.Q.2d
(BNA) at *1–2; BBK Tobacco & Foods LLP, 2020 WL 1285837, at *3.
142. Schuster & Wroldsen, supra note 45, at 118 (discussing historical uncertainty
regarding trademark registrations for CBD-related goods).
143. Examination Guide 1-19: Examination of Marks for Cannabis and Cannabis-Related
Goods and Services After Enactment of the 2018 Farm Bill, supra note 49.
144. Some CBD marks and some Δ8-THC marks will face issues with Food, Drug and
Cosmetic Act and legal use in commerce. See U.S. Trademark Application Serial No.
90,160,477, Office Action (dated Aug. 4, 2021) (Under the FDCA, “[i]t is unlawful to
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Prior to the 2018 Farm Bill, the DEA expressly stated that CBD was a Schedule
I drug.145 However, despite the DEA’s position, some trademark examiners (circa
2016) ignored any Controlled Substances Act issues during the examination of CBDrelated applications despite their obligation to address all grounds for rejection.146
For example, one application for dietary supplements “containing hemp and CBD”
was registered in 2016 without any mention of CBD-related issues.147 Several others
received similar treatment.148
Another approach taken by trademark examiners before the 2018 Farm Bill was
to ask whether the CBD was derived from “industrial hemp”149 or “imported
industrial hemp.”150 Several CBD marks were registered after applicants averred that

introduce food to which CBD, an article that is approved as a new drug, has been added into
interstate commerce or to market CBD as, or in, dietary supplements, regardless of whether
the substances are hemp-derived.”) (internal quotation marks omitted). However, this issue is
beyond the scope of the current research.
145. 81 Fed. Reg. 90194–96 (Dec. 14, 2016). The DEA stated asserted that CBD was a
Schedule I drug prior to this, though the 2016 statement was the first time it was promulgated
in the Federal Register. See, e.g., Press Release, DEA, DEA Eases Requirements for FDAApproved Clinical Trials on Cannabidiol, (Dec. 23, 2015), https://www.dea.gov/pressreleases/2015/12/23/dea-eases-requirements-fda-approved-clinical-trials-cannabidiol
[https://perma.cc/NK65-3PTX] (“CBD is a Schedule I controlled substance as defined under
the CSA.”); Cannabidiol: Barriers to Research and Potential Medial Benefits: Hearing
Before the Caucus on International Narcotics Control, 114th Cong. (2015) (statement of
Joseph T. Rannazzisi, Deputy Assistant Drug Enforcement Administration) (CBD is a
Schedule I drug).
146. TMEP § 704.01 (“The examining attorney’s first Office action must be complete, so
the applicant will be advised of all requirements for amendment and all grounds for refusal.”);
37 C.F.R. § 2.61(a) (2021).
147. U.S. Trademark Application Serial No. 86,512,991 (filed Jan. 23, 2015).
148. See U.S. Trademark Application Serial No. 86,591,721 (filed Apr. 9, 2015) (allowed
on Sept. 15, 2015 without any mention of CBD, the CSA, or lawful use); U.S. Trademark
Application Serial No. 86,532,277 (filed Feb. 11, 2015) (allowed on Sept. 22, 2015 without
any mention of CBD, the CSA, and lawful use); U.S. Trademark Application Serial No.
86,529,465 (filed Feb. 09, 2015) (allowed on Sept. 15, 2015 without any mention of CBD, the
CSA, and lawful use); U.S. Trademark Application Serial No. 86,686,604 (filed July 8, 2015)
(allowed on Jan. 19, 2016, though subsequently abandoned); U.S. Trademark Application
Serial No. 86,455,188 (filed Nov. 14, 2014) (registered on July 5, 2016 with no prosecution).
149. U.S. Trademark Application Serial No. 86,288,363 (filed May 21, 2014), Office
Action (dated June 26, 2014); see also U.S. Trademark Application Serial No. 86,200,648,
Office Action (dated Apr. 3, 2014) (“Is the CBD contained in applicant’s goods derived from
hemp or marijuana?”), U.S. Registration Certificate (dated May 26, 2015); U.S. Trademark
Application Serial No. 86,130,668, Office Action (dated Apr. 3, 2014), Registration
Certificate (dated Oct. 14, 2014); U.S. Trademark Application Serial No. 86,402,862, Office
Action (dated Oct. 27, 2014), Registration Certificate (dated July 7, 2015).
150. See, e.g., U.S. Trademark Application Serial No. 86,534,748, Examiner’s
Amendment/Priority Action (dated May 14, 2015); see also U.S. Trademark Application
Serial No. 86,534,748, Office Action Response (dated June 2, 2015), Examiner’s
Amendment/Priority Action (dated May 14, 2015), Notice of Allowance (dated Sept. 15,
2015); U.S. Trademark Application Serial No. 86,538,367, Examiner’s Amendment/Priority
Action (dated June 3, 2015), Office Action Response (dated July 27, 2015), Notice of

2022]

CANNABIS DERIVATIVES

197

their goods were from this sort of hemp—despite the statements being irrelevant to
the applicable legal standards.151 This sort of uncertainty was common at that time
for CBD applications. Eventually, the Trademark Office changed course by refusing
all CBD-related applications after further guidance from the DEA was issued.152
This was the situation until passage of the 2018 Farm Bill. After that enactment,
the Trademark Office began registering CBD-related marks if the drug was derived
from legal hemp.153 Restated, the Trademark Office is willing to register a Schedule
I drug (CBD),154 so long as it falls within the definition of legal hemp from the Farm
Bill. This point will prove important with regard to consistency in examining Δ8THC applications. Indeed, several themes arising from CBD-mark examination are
also present for Δ8-THC marks.
B. Treatment of Δ8-THC Trademark Applications
The current analysis of the interaction of Δ8-THC marks and the federal
trademark laws begins with a December 31, 2021, Freedom of Information Act
(FOIA) request to the USPTO.155 It requested all communications “to trademark
examiners instructing them on how to examine trademark applications associated

Allowance (dated Nov. 10, 2015).
151. Schuster & Wroldsen, supra note 45, at 150–56 (describing why these distinctions
are legally unimportant).
152. U.S. Trademark Application Serial No. 86,982,881, Office Action (dated Aug. 23,
2017). The communication stated:
The Drug Enforcement Administration has recently changed Schedule 1 of the
CSA to include a new drug code, 7350, for marijuana extract. This definition has
been interpreted to include the cannabinoid CBD. . . . Since applicant is selling
its smokeless vaporizer pipes for the purpose of consuming the CBD liquids, the
goods are unlawful drug paraphernalia under the CSA which is defined to include
any device or equipment designed for use or primarily intended for use in
connection with the ingestion of an unlawful controlled substance.
Id.; 81 Fed. Reg. 90,194–96 (Dec. 14, 2016) (to be codified at 21 C.F.R. Part 1308); 21
C.F.R. § 1308.11 (2016).
153. Examination Guide 1-19: Examination of Marks for Cannabis and Cannabis-Related
Goods and Services After Enactment of the 2018 Farm Bill, supra note 49. Note that federal
courts likewise enforce the hemp/marijuana distinction for federal trademark purposes.
Wunderwerks, Inc., 2021 WL 5771138, at *4.
154. 81 Fed. Reg. 90, 194–96 (Dec. 14, 2016) (to be codified at 21 C.F.R. Part 1308)
(stating that CBD extracts “fall within the new drug code 7350[,]” which is a Schedule I drug.);
21 C.F.R. § 1308.11 (2016).
155. E-mail from Mike Schuster, Assistant Professor, Univ. of Ga., to Custodian of
Records, U.S. Patent & Trademark Office (Dec. 31, 2021, 11:22 AM) (on file with author). In
full, the request sought: “Any communications, promulgations, emails, instructions, or other
correspondence sent to trademark examiners instructing them on how to examine trademark
applications associated with delta-8-tetrahydrocannabinol-related goods or services dated
December 31, 2019 or later.” Id.

198

INDIANA LAW JOURNAL

[Vol. 98:177

with delta-8-tetrahydrocannabinol-related goods.”156 The USPTO’s responsive
documents indicated that a “Delta-8 [Controlled Substances Act] refusal form
paragraph” was drafted in mid-2021.157 Indeed, this form refusal seems to have been
largely adopted.158 As discussed below, many rejections contained similar language
and reached similar results. This standardized approach stands in stark contrast to
the varied responses to early CBD-related applications, though commonalities are
also found.
To further review the treatment of Δ8-THC applications, the USPTO’s Trademark
Electronic Search System was consulted for relevant submissions. Specifically, all
fields searched for were “delta-8,” “delta 8,” or “delta8.” Review of these
applications make several themes clear. As an initial point, the Trademark Office
again diverges from the DEA’s stance on drug legality. With regard to CBD marks,
the USPTO was willing to register marks (implying a belief that CBD was legal)159
during a period that the DEA stated that CBD was illegal.160 In contrast, with regard
to Δ8-THC, the Trademark Office takes the position that the drug is illegal,161 despite
the DEA’s stated opinion to the contrary.162
Looking to why the Trademark Office rejects Δ8-THC applications, some
examiners simply state that “Delta-8 THC is . . . a Schedule I drug,” which therefore
cannot be used in legal commerce.163 This is a proper statement regarding the
Controlled Substances Act,164 but it is an incomplete analysis. As discussed in

156. The FOIA request was identified as request number F-22-00057 by the USPTO. Email from Karon Seldon, USPTO, to Mike Schuster, Assistant Professor, Univ. of Ga. (Feb.
9, 2022, 12:22 PM) (on file with author).
157. E-mails in disclosure accompanying E-mail from Karon Seldon, USPTO, to Mike
Schuster, Assistant Professor, Univ. of Ga. (Feb. 9, 2022, 12:22 PM), dated 21 July 2021,
14:24:53 (entitled: “Delta-8 Form Paragraph”) and dated 21 June 2021, 10:47:34 (entitled:
“Delta-8 RFI Form Paragraph”).
158. Redactions in the documents turned over for the FOIA request were redacted
significantly, especially with regard to internal deliberations. Thus, the actual substance of the
form rejection was not apparent. Rather, the disclosures merely made it apparent that a form
rejection was contemplated and apparently put into place.
159. U.S. Trademark Application Serial No. 86,686,604 (filed July 8, 2015) (allowed on
Jan. 19, 2016, though subsequently abandoned); U.S. Trademark Application Serial No.
86,455,188 (filed Nov. 14, 2014, 86455188) (registered on July 5, 2016, with no prosecution).
160. See, e.g., DEA Eases Requirements for FDA-Approved Clinical Trials on
Cannabidiol, supra note 145 (“CBD is a Schedule I controlled substance as defined under the
CSA.”); Cannabidiol: Barriers to Research and Potential Medial Benefits: Hearing Before
the Caucus on International Narcotics Control, 114th Cong. (2015) (statement of Joseph T.
Rannazzisi, Deputy Assistant Drug Enforcement Administration). (CBD is a Schedule I drug).
161. See, e.g., U.S. Trademark Application Serial No. 90,036,541, Office Action (dated
Oct. 21, 2020); U.S. Trademark Application Serial No. 90,289,354, Office Action (dated Oct.
18, 2021); U.S. Trademark Application Serial No. 90,251,954, Office Action (dated Aug. 4,
2021); U.S. Trademark Application Serial No. 90,160,477, Office Action (dated Aug. 4,
2021).
162. See Letter from Terrence L. Boos to Donna C. Yeatman, supra note 65; see also supra
notes 61–76 and accompanying text (analyzing the DEA’s opinion letter).
163. U.S. Trademark Application Serial No. 90,284,195, Office Action (dated July 23,
2021).
164. Controlled Substances: Alphabetical Order, supra note 24 (listing “THC, Delta-8
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Section 0.0, there are significant arguments (accepted by both the DEA165 and federal
courts)166 that Δ8-THC derived from hemp is legal, as per the 2018 Farm Bill.167
On that point, some examiners have addressed the interaction between Δ8-THC,
legal hemp, and the Farm Bill. Several office actions recognize that hemp and its
derivatives are legal, but then assert that this limitation “does not convert Schedule I
unlawful goods (e.g., delta-8 THC)” into legal goods.168 This approach is curious,
given the Trademark Office’s simultaneous willingness to register Schedule I CBDrelated marks169 if the drug is derived from hemp.170 There is an apparent
contradiction in asserting that the 2018 Farm Bill can convert Schedule I CBD into
a legal drug if derived from hemp, but it cannot convert Schedule I Δ8-THC into a

THC, Delta-9 THC, dronabinol and others” as Schedule I drugs) (emphasis added).
165. See Letter from Terrence L. Boos to Donna C. Yeatman, supra note 65.
166. Minute Order [In Chambers] Amended Order Regarding Motion for Preliminary
Injunction, AK Futures LLC v. Boyd St. Distro, LLC, No. 8:21-cv-01027, 2021 WL 4860513:
Plaintiff AK Futures LLC (“Futures”) moved for a preliminary injunction, ECF No. 29, at 9
(C.D. Cal., Sept. 9, 2021) (citing Notice of Motion and Motion for Preliminary Injunction re
Per FRCP 65 and For Leave to Immediately Commence Discovery filed by Plaintiff AK
Futures LLC, ECF. No. 15, Exhibit 11, Declaration of James Clelland, ¶¶ 2–3) (stating that
“Delta-8 is a hemp-derived product with less than 0.3% of the psychoactive delta-9tetrahydrocannabinol compound and is permitted to be sold in interstate commerce under the
2018 Farm Bill.”); AK Futures LLC, 35 F.4th at 692.
167. See supra text accompanying Section I.C.
168. See, e.g., U.S. Trademark Application Serial No. 90,289,354, Office Action (dated
Oct. 18, 2021); U.S. Trademark Application Serial No. 90,251,954, Office Action (dated Aug.
4, 2021); U.S. Trademark Application Serial No. 90,160,477, Office Action (dated Aug. 4,
2021).
169. Establishment of a New Drug Code for Marihuana Extract, 81 Fed. Reg. 90194,
90194–96 (Dec. 14, 2016) (to be codified at 21 C.F.R. Part 1308) (stating CBD extracts “fall
within the new drug code 7350,” which is a Schedule I drug); Schedule I, 21 C.F.R. § 1308.11
(2016); see also U.S. Trademark Application Serial No. 86,982,881, Office Action (dated
Aug. 23, 2017). The examiner for that application stated:
The Drug Enforcement Administration has recently changed Schedule 1
of the CSA to include a new drug code, 7350, for marijuana extract. This
definition has been interpreted to include the cannabinoid CBD. . . . Since
applicant is selling its smokeless vaporizer pipes for the purpose of
consuming the CBD liquids, the goods are unlawful drug paraphernalia
under the CSA which is defined to include any device or equipment
designed for use or primarily intended for use in connection with the
ingestion of an unlawful controlled substance.
Id.
170. Examination Guide 1-19: Examination of Marks for Cannabis and Cannabis-Related
Goods and Services After Enactment of the 2018 Farm Bill, supra note 49 (“[T]he 2018 Farm
Bill potentially removes the CSA as a ground for refusal of registration, but only if the goods
are derived from ‘hemp.’ Cannabis and CBD derived from marijuana (i.e., Cannabis sativa L.
with more than 0.3% THC on a dry-weight basis) still violate federal law.”).
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legal drug if derived from hemp. Given that both Δ8-THC and CBD are legally
indistinguishable (i.e., both are Schedule I drugs),171these stances seem inconsistent.
Several office actions present an additional argument explaining that the Farm
Bill’s definition of legal hemp does not include most Δ8-THC. The position begins
with the factual assertion that Δ8-THC exists in low concentrations in legal hemp,
and commercially available Δ8-THC is commonly produced via chemical alteration
of CBD derived from hemp.172 From there, the trademark examiners recognize that
legal hemp and its “derivatives, extracts, [and] isomers” are legal, but they assert that
Δ8-THC created from chemically altered CBD does not fall within this definition.173
The argument thus hinges on the interpretation of hemp’s “derivatives, extracts,
[and] isomers” as presented in the Farm Bill. Indeed, looking only to the language
of the Farm Bill, reasonable minds could potentially differ on this interpretation.174
This is not, however, a legitimate reason to reject Δ8-THC applications. The next
subsection shows that relevant Trademark Office policies and tenets of
administrative law favor registration of marks for Δ8-THC made by chemical
alteration of hemp-derived CBD.
C. USPTO Policies Favor Δ8-THC Registration
Any arguable uncertainty surrounding Δ8-THC should not prevent the USPTO
from registering related trademarks for several reasons beyond the substantive
question of legality. Initially, the USPTO should defer to the DEA on matters of drug
policy. Second, USPTO policy favors invoking the “illegal” use-in-commerce
doctrine only when clearly applicable.175 Given the current uncertainty in the law,
Δ8-THC derived from hemp is not “clearly” illegal.
Deference should be afforded to federal agencies regarding the “interpretation of
a statute it is entrusted to administer.”176 This is the case with regard to the DEA’s

171. Controlled Substances: Alphabetical Order, supra note 24.
172. See, e.g., U.S. Trademark Application Serial No. 90,036,541, Office Action (dated
Oct. 21, 2020); U.S. Trademark Application Serial No. 90,289,354, Office Action (dated Oct.
18, 2021); U.S. Trademark Application Serial No. 90,251,954, Office Action (dated Aug. 4,
2021); U.S. Trademark Application Serial No. 90,160,477, Office Action (dated Aug. 4,
2021).
173. Indeed, on this point, some examiners have assumed that Δ8-THC is synthesized from
CBD, but then have specifically asked the applicant to clarify the point. For example, one
examiner asked the applicant to “[d]escribe the process by which the delta-8 THC in
applicant’s goods is obtained,” after stating that most Δ8-THC comes from CBD. U.S.
Trademark Application Serial No. 90,222,407, Office Action (dated Oct. 21, 2021).
174. The Ninth Circuit does not, however, share this interpretation. Indeed, it posits that
there is no reasonable interpretation of the 2018 Farm Bill other than that Δ8-THC derived
from chemically altered CBD from hemp is legal. AK Futures LLC, 35 F.4th at 690.
175. Examination Guide 1-19: Examination of Marks for Cannabis and Cannabis-Related
Goods and Services after Enactment of the 2018 Farm Bill, supra note 49 (“The United States
Patent and Trademark Office (USPTO) refuses to register marks for goods and/or services that
show a clear violation of federal law, regardless of the legality of the activities under state
law.”) (emphasis added).
176. Serrano v. Berryhill, No. EP-15-CV-132-MAT, 2018 WL 1309861, at *5 (W.D. Tex.
Mar. 13, 2018) (citing Chevron, U.S.A., Inc. v. Nat. Res. Def. Council, Inc., 467 U.S. 837,
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interpretation of the Controlled Substances Act.177 This deference is not, however,
absolute. Opinion letters—such as the DEA’s September 2021 letter regarding the
legality of Δ8-THC derived from hemp—do not receive the strong deference given
to a final agency rule.178 In the current case, the Agency’s opinion may be “entitled
to respect” if persuasive.179
The Supreme Court instructs that the persuasiveness of an agency’s opinion is a
function of whether it is consistent with statutory text, legislative purpose, and prior
positions taken by the agency.180 The Δ8-THC opinion letter does not diverge from
prior interpretations of the 2018 Farm Bill. In fact, it is consistent with earlier
distinctions between “synthetic” (i.e., derived only from chemicals) and nonsynthetic (i.e., derived from hemp) drugs with regard to the Controlled Substances
Act.181 Further, as there is no compelling statement of purpose for the 2018 Farm
Bill, the DEA’s interpretation is not inconsistent with its purpose.182 Lastly, the
DEA’s expertise in interpreting the Controlled Substances Act favors deference in
its interpretation.183 Taken in sum, the DEA’s opinion regarding the legality of Δ8THC derived from hemp is warranted some deference.
Beyond this, there is an argument that the question of deference to the DEA’s
opinion letter is not even relevant. An agency has no need to opine on a statute’s
interpretation where its meaning is clear.184 To this point, the Ninth Circuit held that

844 (1984)).
177. See United States v. Kelly, No. 2:15-cr-00041, 2016 WL 8732182, at *6 (D. Nev.
Apr. 15, 2016), report and recommendation adopted, No. 2:15-CR-0041, 2016 WL 3769339
(D. Nev. July 14, 2016), aff'd, 874 F.3d 1037 (9th Cir. 2017) (“[T]he Court gives deference to
the DEA's statutory interpretation of the CSA. . . .”).
178. An agency’s final rule may be entitled to strong (Chevron) deference. Teva Pharms.
USA, Inc. v. FDA, 514 F. Supp. 3d 66, 97 (D.D.C. 2020). However, “[i]nterpretations such as
those in opinion letters—like interpretations contained in policy statements, agency manuals,
and enforcement guidelines, all of which lack the force of law—do not warrant Chevron-style
deference.” Christensen v. Harris Cnty., 529 U.S. 576, 587 (2000); see also Hagans v. Comm’r
of Soc. Sec., 694 F.3d 287, 300 n.14 (3d Cir. 2012); Packard v. Pittsburgh Transp. Co., 418
F.3d 246, 252–53 (3d Cir. 2005).
179. Christensen, 529 U.S. at 587
180. Hagans, 694 F.3d at 304.
181. Drug Enforcement Administration’s Implementation of the Agriculture Improvement
Act of 2018, 85 Fed. Reg. 51639, 51641 (Aug. 21, 2020) (to be codified at 21 C.F.R. pts. 1308,
1312) (“All synthetically derived tetrahydrocannabinols remain schedule I controlled
substances,” as opposed to those derived from legal hemp); Letter from Terrence L. Boos to
Donna C. Yeatman, supra note 65 (contrasting Δ8-THC “synthetically produced from noncannabis materials” and Δ8-THC found “in or derived from” hemp).
182. See, e.g., AK Futures LLC v. Boyd St. Distro, LLC, 35 F.4th 682, 693 (9th Cir. 2022)
(disregarding arguments “Congress intended the Farm Act to legalize only industrial hemp,
not a potentially psychoactive substance” that were based on a single quote from a legislator).
Some parties argue that legal Δ8-THC sales violate the spirit of the 2018 Farm Bill, if not the
law itself. McWilliams, Goff & Williams, supra note 2 (Some “have argued [this] result
violates the spirit of the [2018 Farm Bill, which was] to legalize the non-psychotropic aspects
of the cannabis plant.”). However, this is insufficient to find the DEA’s opinion to be
inconsistent with any statement of purpose associated with the 2018 Farm Bill.
183. Hagans, 694 F.3d at 305.
184. Bd. of Governors of Fed. Rsrv. Sys. v. Dimension Fin. Corp., 474 U.S. 361, 374
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the plain meaning of the 2018 Farm Bill is absolutely certain and allows for no
conclusion except that Δ8-THC derived from hemp is legal.185
Further, the USPTO maintains a practice of presuming the legality of a use in
commerce, unless the application shows a clear “violation of federal law.”186 On this
point, the Trademark Manual of Examining Procedure favors deference to a “court
or . . . federal agency responsible for overseeing activity” that has addressed the
relevant issue.187 The USPTO’s Trademark Trial and Appeal Board gives similar
instructions. Recognizing the Agency’s relative unfamiliarity with other areas of the
law (e.g., the Controlled Substances Act), it stated in a precedential opinion that
deference should be given to determinations of relevant agencies or federal courts.188
Both the DEA and the Ninth Circuit opined that Δ8-THC from hemp is a legal
drug.189 Thus, it is inconsistent with internal guidelines for the USPTO to reject Δ8THC applications for not being used in legal commerce.190
A final point on statutory interpretation and deference is warranted. The USPTO
has repeatedly stated in office actions that Δ8-THC derived through chemical
alteration of CBD derived from hemp is “synthetic” and, therefore, illegal under the
Controlled Substances Act.191 In each instance, the examiner cited a Forbes.com
article for the proposition that “Delta-8 products are made synthetically from

(1986); Doe v. Miller, 573 F. Supp. 461, 467 (N.D. Ill. 1983) (“[C]ourts should not defer to
an agency’s opinion when, as in this case, it is inconsistent with the clear meaning of a statute
as revealed by its language, purpose, and history.”).
185. AK Futures LLC, 35 F.4th at 692; Letter from Terrence L. Boos to Donna C.
Yeatman, supra note 65.
186. In re Stanley Bros. Soc. Enterps., LLC, No. 86568478, 2020 WL 3288093, at *5–6
(T.T.A.B. June 16, 2020); TMEP § 907 (“Generally, the USPTO presumes that an applicant’s
use of the mark in commerce is lawful and does not inquire whether such use is lawful unless
the record or other evidence shows a clear violation of law.”) (emphasis added).
187. TMEP § 907 (stating that examiners “must inquire about compliance with federal
laws or refuse registration based on the absence of lawful use in commerce when a court or
the responsible federal agency has issued a finding of noncompliance under the relevant statute
or where there has been a per se violation of the relevant statute”).
188. In re Stanley Bros. Soc. Enterps., LLC, No. 86568478, 2020 WL 3288093, at *5–6
(T.T.A.B June 16, 2020).
189. AK Futures LLC, 35 F.4th at 690; Letter from Terrence L. Boos to Donna C.
Yeatman, supra note 65.
190. It is notable that Δ8-THC is illegal under some state laws. This is unimportant for
purposes of USPTO policy. In re Stanley Bros. Soc. Enterprises, LLC, No. 86568478, 2020
WL 3288093, at *5–6 (T.T.A.B. June 16, 2020) (asking whether a use is legal under federal
law); TMEP § 907 (Examiners “must inquire about compliance with federal laws or refuse
registration based on the absence of lawful use in commerce.”) (emphasis added).
191. U.S. Trademark Application Serial No. 90,036,541, Office Action (dated Oct. 29,
2021); U.S. Trademark Application Serial No. 90,522,254, Office Action (dated Nov. 14,
2021); U.S. Trademark Application Serial No. 90,520,933, Office Action (dated Oct. 23,
2021); U.S. Trademark Application Serial No. 90,289,354, Office Action (dated Oct. 18,
2021); U.S. Trademark Application Serial No. 90,251,954, Office Action (dated Aug. 4,
2021); U.S. Trademark Application Serial No. 90,160,477, Office Action (dated Aug. 4,
2021); U.S. Trademark Application Serial No. 90,343,170, Office Action (dated Aug. 20,
2021); U.S. Trademark Application Serial No. 90,562,035, Office Action (dated Dec. 13,
2021).
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CBD.”192 Reliance on this citation is improper for two reasons. First, Forbes’s use of
the term “synthetic” does not necessarily mean the same thing as when the DEA
states that Δ8-THC “synthetically produced from non-cannabis materials” is a
Schedule I drug.193 The mere fact that a popular news outlet uses the term “synthetic”
does not mean that the relevant legal standard is satisfied. Second, citing to a news
website for legal conclusions might be appropriate before the relevant federal agency
opines on the matter. However, the USPTO continues to cite to the Forbes article
into 2022194—after the DEA’s opinion letter was issued in September 2021.195
III. THE IMPORTANCE OF DELTA-8 THC REGISTRATIONS
The above discussions of trademark registrations for Δ8-THC have real-world
implications. Initially, these registrations are strategically valuable to market
competitors hoping to develop goodwill in the Δ8-THC market and create potential
first mover advantages if cannabis products become generally legal. Second,
registration of these marks incentivizes the creation of quality products in the
industry.196 This, in turn, mitigates concerns that Δ8-THC firms sell products created
using unsafe ingredients197 or with insufficient quality control to remove harmful
chemicals.198

192. Will Yakowicz, Delta-8 THC Offers a Legal High, but Here’s Why the Booming
Business May Soon Go Up in Smoke, FORBES (Mar. 12, 2021) https://www.forbes.com/
sites/willyakowicz/2021/03/12/delta-8-thc-offers-a-legal-high-but-heres-why-the-boomingbusiness-may-soon-go-up-in-smoke/ [https://perma.cc/ZQ9H-7HQP].
193. Letter from Terrence L. Boos to Donna C. Yeatman, supra note 65.
194. See U.S. Trademark Application Serial No. 90,036,541, Office Action (dated Jan. 21,
2022).
195. U.S. Trademark Application Serial No. 90,562,035, Office Action (dated Dec. 13,
2021) (almost two months after the DEA’s letter was issued); U.S. Trademark Application
Serial No. 90,522,254, Office Action (dated Nov. 14, 2021); U.S. Trademark Application
Serial No. 90,520,933, Office Action (dated Oct. 23, 2021); U.S. Trademark Application
Serial No. 90,289,354, Office Action (dated Oct. 18, 2021); U.S. Trademark Application
Serial No. 90,036,541, Office Action (dated Oct. 29, 2021). Indeed, the DEA’s letter has been
cited by the USPTO. U.S. Trademark Application Serial No. 90,036,541, Office Action
Response (dated Dec. 1, 2021). The Trademark Office has made a similar, if less obvious error
in citing to the FDA website for the proposition that “additional chemicals are needed to
convert other cannabinoids in hemp, like CBD, into delta-8 THC (i.e., synthetic conversion).”
U.S. Trademark Application Serial No. 90,036,541, Office Action (dated Jan. 21, 2022)
(emphasis added). Again, the fact that the FDA makes a broad assertion that Δ8-THC is made
through a “synthetic conversion” does not necessarily mean that the Δ8-THC is “synthetically
produced from non-cannabis materials” and thus, satisfies the DEA’s standard for Schedule I
treatment. Letter from Terrence L. Boos to Donna C. Yeatman, supra note 65.
196. See Katya Assaf, The Dilution of Culture and the Law of Trademarks, 49 IDEA 1, 77
(2008).
197. 5 Things to Know about Delta-8 Tetrahydrocannabinol–Delta-8 THC, FDA,
https://www.fda.gov/consumers/consumer-updates/5-things-know-about-delta-8tetrahydrocannabinol-delta-8-thc [https://perma.cc/CH2K-ECU8] (“Some manufacturers may
use potentially unsafe household chemicals to make delta-8 THC.”).
198. Erickson, supra note 66 (describing Δ8-THC products that contain “by-products and
other unwanted compounds”).
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A. Private Strategic Benefits
There is a growing body of literature on strategic behavior within the U.S.
cannabis industry.199 This research describes how firms seeking competitive
advantage in this market navigate a legal environment characterized by constant
regulatory change and inconsistent enforcement of relevant laws.200 Application of
the lessons from this literature explains many firms’ recent choices to enter a legally
unsettled Δ8-THC market. Furthermore, that research also rationalizes firms’
decisions to pursue Δ8-THC trademark registrations, even though doing so requires
admitting that it is selling the drug201 while some uncertainty regarding the legality
of Δ8-THC continues to exist.
In cannabis markets, firms must determine their level of risk aversion regarding
future regulatory change, interpretation, and enforcement.202 Examples of this
uncertainty in the industry include the disagreement between the USPTO and the
DEA regarding the legality of Δ8-THC203 and the varied enforcement choices made

199. Colleen M. Baker, Entrepreneurial Regulatory Legal Strategy: The Case of
Cannabis, 57 AM. BUS. L.J. 913, 915 (2020); Peter Bowal, Kathryn Kisska-Schulze, Richard
Haigh & Adrienne Ng, Regulating Cannabis: A Comparative Exploration of Canadian
Legalization, 57 AM. BUS. L.J. 677, 708 (2020); Mark J. Cowan, Taxing Cannabis on the
Reservation, 57 AM. BUS. L.J. 867, 911 (2020).
200. Schuster & Bird, supra note 83, at 373 (describing “substantive uncertainty” and
“enforcement uncertainty” surrounding the cannabis industry). Professor Bird describes five
tiers of legal strategy. See Robert C. Bird, Pathways of Legal Strategy, 14 STAN. J.L. BUS. &
FIN. 1, 17 (2008); Robert C. Bird & David Orozco, Finding the Right Corporate Legal
Strategy, 56 MIT SLOAN MGMT. REV. 81, 82–86 (2014). An unsophisticated approach to
navigating a legal environment is to attempt to avoid or turn a deaf ear to legal obligations and
consequence. Robert C. Bird & David Orozco, Finding the Right Corporate Legal Strategy,
56 MIT SLOAN MGMT. REV. 81, 82 (2014). This is called avoidance. Compliance is a second
tier of strategy where a firm recognizes that legal obligations are a cost of business and
attempts to conform to these requirements. Robert C. Bird, Pathways of Legal Strategy, 14
STAN. J.L. BUS. & FIN. 1, 17 (2008). Prevention firms will proactively take steps to avoid
future legal complications, including employee training and proactively planning for future
obligations. Id.at 23–26. The apex of legal strategy is most sophisticated means of strategically
navigating the legal environment are advantage (using legal acumen to create proactive
benefits). Robert C. Bird & David Orozco, Finding the Right Corporate Legal Strategy, 56
MIT SLOAN MGMT. REV. 81, 84–85 (2014), and transformation (creating repeated, sustainable
value through strategic legal behaviors); Robert C. Bird, Pathways of Legal Strategy, 14 STAN.
J.L. BUS. & FIN. 1, 14 (2008); see also Mike Schuster, David Mitchell & Kenneth Brown.,
Sampling Increases Music Sales: An Empirical Copyright Study, 56 AM. BUS. L.J. 177, 210–
13 (2019) (describing how copyright policing costs can be transformed into a revenue source).
201. Emily Pyclik, Obstacles to Obtaining and Enforcing Intellectual Property Rights in
the Marijuana Industry, 9 AM. U. INTELL. PROP. BRIEF 26, 44–45 (2018); Sam Kamin & Viva
R. Moffat, Trademark Laundering, Useless Patents, and Other IP Challenges for the
Marijuana Industry, 73 WASH. & LEE L. REV. 217, 247 (2016).
202. See Schuster & Bird, supra note 83, at 385–86 (describing uncertainty in the cannabis
industry).
203. See Letter from Terrence L. Boos to Donna C. Yeatman, supra note 65 (stating that
Δ8-THC created from hemp is legal); U.S. Trademark Application Serial No. 90,284,195,
Office Action (dated July 23, 2021) (stating that Δ8-THC is illegal).
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by U.S. presidents over the last few decades.204 Depending on their risk tolerance,
companies must decide whether to move forward with cannabis-based business plans
or delay until the regulatory environment is more certain.
Firms taking the “safe” approach engage in what the law and strategy literature
calls “compliance” strategies.205 Compliance firms recognize legal obligations and
interpret these standards conservatively to avoid illegal behaviors.206 This “wait and
see” approach insulates the firm from possible legal consequences, but as described
below, this choice may have significant competitive drawbacks in the cannabis
industry.
Compliance firms differ from firms practicing “avoidance” strategies.207
Avoidance firms choose to circumvent legal obligations208 or interpret the law in a
self-serving manner to avoid legal hurdles.209 This approach is not usually viewed as
a mature strategy210 because a firm often reaches a bad end when legal obligations
and enforcement behaviors catch up to it. However, the cannabis and Δ8-THC
markets may be outliers where avoidance is a strategically beneficial approach,
relative to compliance. This theme holds true for decisions to both enter the Δ8-THC
market and to seek federal trademark protection for those goods.
Firms practicing an avoidance strategy will proceed in the Δ8-THC market
without regard to limitations arising from relevant law (i.e., the Controlled
Substances Act).211 Assuming commercial success, they will develop goodwill and
a customer base in the Δ8-THC market while competitors practicing compliance
strategies wait on the sideline. This risk-inducing “avoidance” strategy creates
potential legal exposure212 (and raises ethical questions arising from ignoring
pertinent legal issues).213 However, firms have been willing to enter the market

204. See supra notes 95–97 and accompanying text.
205. See Bird, supra note 200, at 17 (“[C]ompliance firms view their legal resources as
cost centers. Adherence to legal rules is a necessary expense of doing business. Compliance
firms, however, do not pursue illegal behavior to avoid costs.”); Bird & Orozco, supra note
200, at 83–84 (“Companies operating in the compliance pathway recognize that the law is an
unwelcome but mandatory constraint on their activities. In such companies, managers view
compliance mainly as a cost that needs to be minimized.”).
206. Bird, supra note 200, at 17.
207. Bird & Orozco, supra note 200, at 82 (“[Avoidance firms] make the conscious choice
to disregard or remain willfully blind to the legal consequences of their company’s actions.
The prevailing attitude in such cases is that the law presents an obstacle to their desired
business goals.”).
208. See Bird & Orozco, supra note 200, at 82.
209. Bird, supra note 200, at 14.
210. Schuster & Bird, supra note 83, at 385.
211. See Leas, supra note 3, at 1928 (stating legal loopholes “have created a new
marketplace for delta-8-THC products that uses sophisticated sourcing and distribution
strategies designed to evade cannabis and hemp laws and appeal to consumers but also
resemble a legitimate business”). For a general discussion of strategy and legal loopholes, see
generally Daniel T. Ostas, Corporate Counsel, Legal Loopholes, and the Ethics of
Interpretation, 18 TEX. WESLEYAN L. REV. 703 (2012); Daniel T. Ostas, The Ethics of
Corporate Legal Strategy: A Response to Professor Mayer, 48 AM. BUS. L.J. 765 (2011).
212. Bird & Orozco, supra note 200, at 82–83.
213. See Robert Hughes, Doing the Right Thing: When Moral Obligation is Enough,
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despite these concerns.214 Implicitly, they are deciding that the future strategic and
immediate commercial benefits outweigh any legal concerns,215 especially given the
generally relaxed enforcement of anti-cannabis regulations.216
Competition among firms that enter the Δ8-THC market (and the cannabis market
generally) create another set of strategic choices. Within consumer goods markets, a
firm’s trademarks may be among its most valuable assets.217 Federal registration is
not, however, generally available for traditional cannabis goods (i.e., marijuana).218
Moreover, if a firm chooses to seek federal registration for its cannabis or Δ8-THC
mark, it must aver that it is using the mark in business (e.g., selling cannabis or Δ8THC).219 This could be admitting to criminal behavior in a sworn statement.220 These
factors must be taken into account when deciding a trademark strategy in this market.

KNOWLEDGE@WHARTON (Nov. 19, 2015), https://knowledge.wharton.upenn.edu/article/
doing-the-right-thing-when-moral-obligation-is-enough/
[https://perma.cc/3YYZ-VK5U];
see also Robert C. Hughes, Breaking the Law Under Competitive Pressure, 38 LAW & PHIL.
169, 169 (2019) (asking if firms are morally required to obey laws while competitors break
them to seek advantage).
214. See Schuster & Bird, supra note 83, at 386 (describing the current cannabis legal
environment as presenting “cannabis firms with the problematic question of whether to avoid
running afoul of cannabis regulations or deliberately ignore prohibitions that formally exist
but are largely unenforced”).
215. Indeed, it could be argued that Δ8-THC firms actually take a strategically advanced
position by recognizing the legal prohibition on traditional cannabis (i.e., marijuana) and
turning this into a competitive advantage by selling an arguably legal marijuana alternative
(Δ8-THC).
216. See Tom Angell, supra note 95 (describing Congress’ 2019 choice to prevent certain
cannabis enforcement activities at a federal level); Trevor Hughes, New Marijuana Laws in
2019 Could Help Black and Latino Drug Dealers Go Legal, USA TODAY (Feb. 24, 2019),
https://www.usatoday.com/story/news/2019/02/21/marijuana-legalization-2019-black-latinodealers-now-getting-help/2838959002/ [https://perma.cc/A5QG-92VZ] (describing the low
level penalties associated with cannabis in Oakland, California); Katherine Berger, Note,
ABCs and CBD: Why Children with Treatment-Resistant Conditions Should Be Able to Take
Physician-Recommended Medical Marijuana at School, 80 OHIO STATE L.J. 309, 328 (2019).
217. Doyle, supra note 109, at 2.
218. Stephanie Geiger-Oneto & Robert Sprague, Cannabis Regulatory Confusion and Its
Impact on Consumer Adoption, 57 AM. BUS. L.J. 735, 751 (2020); see In re JJ206, LLC, 120
U.S.P.Q.2d (BNA) at *2; see also In re Morgan Brown, 119 U.S.P.Q.2d (BNA), at *1–2; BBK
Tobacco & Foods LLP, 2020 WL 1285837, at *3 (D. Ariz. Mar. 18, 2020).
219. See, e.g., 37 C.F.R. § 2.20 (2021) (describing a declaration regarding a trademark
application recognizing that “willful false statements [in the application] . . . are punishable
by fine or imprisonment, or both, under (18 U.S.C. 1001), and that such willful false
statements and the like may jeopardize the validity of the application or document or any
registration resulting therefrom”).
220. Pyclik, supra note 201, at 34 (“If a trademark owner admits that their mark is
associated with illegal goods in commerce, this is perilous because a trademark owner will
risk federal criminal prosecution by admitting this on the record.”); Kamin & Moffat, supra
note 201, at 247 (asserting use in commerce with regard to a marijuana mark “would be an
admission, under oath, that the owner of the mark is violating the Controlled Substances Act”);
Dustin Boone, Note, Puff, Puff, Patent: Identifying and Addressing the Tensions Between the
Medical Marijuana Industry, Patent Law, and the Controlled Substances Act, 38 CARDOZO
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Firms pursuing a conservative trademark strategy may engage in “trademark
laundering”—the act of registering a mark in some field related to cannabis.221 For
example, a firm could secure a registration for “Super Green” for ashtray products,
while it simultaneously uses that mark for ashtrays and cannabis goods. This strategy
hopes that parties searching the trademark registry might find the “Super Green”
registration and then decide to not adopt the name to avoid any potentially costly
legal entanglements. These legal entanglements could come from a trademark owner
asserting a meritorious infringement claim or from a hyper-aggressive party asserting
a losing claim that is still expensive to deal with.222
This potential for litigation (or threatened litigation) could create de facto
deterrence that prevents others from later adopting the relevant trademark.223 Thus,
from a conservative strategic perspective, the applicant benefits by not having to aver
that it is selling potentially illegal Δ8-THC or cannabis because it is only seeking
protection for ashtrays (or similar non-cannabis products).224 This behavior
represents an avoidance strategy where the firm recognizes a legal impediment and
chooses to sidestep it while arguably distorting the regulation’s intent.225 But while
this approach reduces legal risk, it also limits the potential upside. Trademark
laundering creates no actual trademark rights in cannabis-specific goods; as
described below, this limitation is significant from a strategy perspective.
Other firms are willing to undertake greater legal risk in exchange for greater
commercial and strategic returns. Beginning in 2020, applicants began to submit
trademark filings where they admit to selling (potentially illegal) Δ8-THC in

ARTS & ENT. L.J. 473, 486 (2020) (“Additionally, if an individual is forthcoming and states in
their trademark application that the trademark is associated with marijuana, they risk opening
themselves up to federal criminal prosecution for admitting this under oath.”).
221. Kamin & Moffat, supra note 201, at 251–52.
222. The primary cost arising from a losing claim would be attorney’s fees. The defendant
can potentially recover attorney’s fees if it establishes that the case is “exceptional.” 15
U.S.C.A. § 1117 (West). To recover under this rule, the defendant must both win at trial and
then establish that the plaintiff’s behavior satisfied the standard for an award of attorney’s
fees. 87 C.J.S. Trademarks, Etc. § 373.
223. This dissuasion technique is particularly effective against firms that are just starting
to consider adopting a new mark, and thus, have invested very little in the mark relative to the
cost of potential litigation and having to rebrand if they lose the lawsuit. Stacey Dogan,
Bullying and Opportunism in Trademark and Right-of-Publicity Law, 96 B.U. L. REV. 1293,
1313 n.92 (2016); see Upjohn Co. v. Am. Home Prods. Corp., No. 1:95CV237, 1996 WL
33322175, at *24 (W.D. Mich. Apr. 5, 1996) (describing “the ease with which a different mark
could have been selected”).
224. Indeed, it appears that firms may be engaging in trademark laundering regarding Δ8THC goods. For example, one application seeks registration of a mark for use with clothing
goods that will likewise be used for Δ8-THC products. See U.S. Trademark Application Serial
No. 97,010,593 (filed Sept. 3, 2021) (asserting use in multiple international classes, including
025 (for “[c]lothing, namely, t-shirts, sweatshirts, polo shirts, jackets, tops, pants, shorts,
dresses, headwear, and hats”) and 030 (for “cookies and brownies . . . containing CBD and
Delta-8 tetrahydrocannabinol (THC) extracts.”)); see also U.S. Trademark Application Serial
No. 97,061,834 (filed Oct. 6, 2021) (for “DELTA 8 ACCESSORIES”) (emphasis added).
225. See Schuster & Bird, supra note 83, at 385–86.
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commerce.226 Undertaking this risk (i.e., filing a Δ8-THC application) may bring
about two distinct benefits. The first can be characterized as an avoidance strategy.
If the firm is willing to subject itself to the legal uncertainty surrounding Δ8-THC
sales, it may reap the reward of trademark protections that are specific to that
industry. In contrast to trademark laundering—which relies on extra-legal deterrent
effects—a trademark registration creates actual legal rights within the Δ8-THC
market. Restated, if a party can secure a Δ8-THC trademark registration, they have
a nationwide right to sue others who adopt their mark for Δ8-THC sales.227 This
protection is significantly stronger than trademark laundering—which relies on de
facto deterrence arising from risk averse firms’ decisions to avoid potential litigation.
That reason alone will incentivize some parties to continue to attempt to secure Δ8THC registrations.
A second benefit is more forward thinking. While the Δ8-THC market is growing,
it remains miniscule relative to what the cannabis market could be if state and federal
regulation continues to recede.228 A recent report from Barclays estimated that the
domestic cannabis market would be worth twenty-eight billion dollars if it were
legalized at the federal level.229 Should this occur, firms with an established brand
will have significant first-mover advantages.230 Prior Δ8-THC registrations further
this goal, despite the fact that the trademark’s scope does not technically cover
marijuana or delta-9 tetrahydrocannabinol (i.e., a registration for Δ8-THC goods
technically only covers Δ8-THC).
Federal trademark registration gives the owner nationwide rights to exclusive use
of a mark for a particular type of product and associated goods.231 Given the

226. See supra Section 0.0 and accompanying text (discussing the identification of Δ8THC trademark applications).
227. This assumes that the defendant did not adopt the mark before the plaintiff began
using it in commerce.
228. Chris Roberts, The Feds Are Coming for Delta-8 THC, FORBES (Sept. 17, 2021, 3:59
PM), https://www.forbes.com/sites/chrisroberts/2021/09/17/the-feds-are-coming-for-delta-8thc/?sh=1f5fd4c06d27 [https://perma.cc/YXN2-5K8S] (“If the Delta-9 THC in marijuana was
legal, demand for Delta-8 THC—a synthetic product, created to fulfill the market inefficiency
posed by drug prohibition—would evaporate. If federal marijuana legalization happens, Delta8 will be a nonfactor.”); see Jonathan Boyar, Unlocking Value in the Cannabis Market Jim
Hagedorn Has a Strategy for Navigating Legalization, FORBES (Jan. 6, 2022, 12:55 PM),
https://www.forbes.com/sites/jonathanboyar/2022/01/06/unlocking-value-in-the-cannabismarket-jim-hagedorn-has-a-strategy-for-navigating-legalization/?sh=3711e34a7e03
[https://perma.cc/4AP5-9DWY] (“Legalization at the state level has created a burgeoning
market, which is expected to grow rapidly, from an estimated $20 billion in 2020 to nearly
$200 billion by 2028.”).
229. Michael Sheetz, Barclays Estimates US Weed Market Would be $28 Billion if
Legalized Today, Growing to $41 Billion by 2028, CNBC (May 1, 2019, 9:38 AM),
https://www.cnbc.com/2019/05/01/barclays-us-cannabis-market-28-billion-if-legalizedtoday.html [https://perma.cc/HG5M-KCKG].
230. Schuster & Bird, supra note 83, at 394.
231. Irene Calboli, The Sunset of “Quality Control” in Modern Trademark Licensing, 57
AM. U. L. REV. 341, 348 (2007) (“[T]he core of trademark rights resides in the ability of
trademark owners to exclude unauthorized parties from using similar marks on identical or
confusingly similar products.”) (citing Lanham Act § 1, 15 U.S.C. § 1051 (2000 & Supp. V
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similarity of Δ8-THC to delta-9 tetrahydrocannabinol (e.g., chemical structure,
psychoactive effects, etc.),232 a Δ8-THC registration likely creates rights with regard
to cannabis goods generally—if the latter becomes federally legal.233 Accordingly,
firms that began generating brand recognition and goodwill through Δ8-THC sales
will enjoy significant first-mover advantages over their competitors within the
general cannabis market.234
Forward-thinking legal approaches of this nature are “advantage” strategies
because they represent the use of legal acumen to create proactive benefits for the
firm.235 Indeed, given the relative nascence of the cannabis market, such advanced
strategies are uncommon in the field.236 Recognition of this strategic value explains
why firms are wise to value Δ8-THC registrations and why they have taken steps to
secure these protections.
While Δ8-THC applications have not proven to be successful to this point, this
does not foreclose the possibility of registration going forward. The USPTO has
previously shown a willingness to vary its approach to earlier cannabis derivatives,
especially in the presence of an ambiguous legal environment.237 Indeed, Δ8-THC
applicants are attempting to further their own goals by increasing legal ambiguity in
ways that prior CBD applicants did.
In early CBD trademark applications (i.e., before CBD was easily registerable238),
parties would often make dubious legal claims that seemed reasonable while CBD

2005)); Alexa Lewis, Respecting Third-Party Intellectual Property Rights on the Internet,
FED. LAW. 12, 13 (2011) (“[T]he trademark owner has the right to exclude others from using
the similar marks in association with similar products and services if doing so will cause
consumers to be confused in connection with the source of those products and services.”).
232. See Robert McCoppin, Boom Time for Marijuana Sales in Illinois, as Industry
Expands with New Products — but Minority Businesses Get Left Behind, CHI. TRIB. (Jan. 1,
2022, 5:00 AM), https://www.chicagotribune.com/marijuana/illinois/ct-illinois-marijuana2021-review-20220101-6ltav5lghfba3awognltyrzs4m-story.html [https://perma.cc/SQ6M2NC7] (referring to Δ8-THC as “weed [i.e., delta-9 tetrahydrocannabinol] light”); Jordyn
Noennig, Delta-8-THC Sold in Wisconsin Can Get Users High, MILWAUKEE J. SENTINEL (Jan.
5, 2022, 6:01 AM), https://www.jsonline.com/story/entertainment/2022/01/05/delta-8wisconsin-known-weed-light-openly-sold-across-state/8824846002/ [https://perma.cc/78SEEPNA] (same).
233. See Schuster & Bird, supra note 83, at 394 (“Parties that have already cultivated brand
value in th[e CBD] market can expect their investments to blossom as cannabis moves towards
the possibility of full federal legalization.”); Schuster & Wroldsen, supra note 45, at 159–60
(“In the face of continually evolving marijuana laws, forward-thinking legal strategists may
identify today's CBD trademarks as the cornerstone for future trademark protection in the
much broader and more lucrative legal marijuana market.”). This behavior has previously been
described with regard to CBD-marks. Schuster & Bird, supra note 83, at 394. While the
strategic benefits of a CBD registration are significant, a Δ8-THC trademark is more likely to
cover marijuana/delta-9 tetrahydrocannabinol and thus, it is more strategically valuable. This
is because Δ8-THC is closer to traditional marijuana in its use (commonly for its psychoactive
effects), as compared to non-psychoactive CBD.
234. Schuster & Bird, supra note 83, at 394.
235. See Bird & Orozco, supra note 200, at 84–85.
236. See Schuster & Bird, supra note 83, at 394–95.
237. See Schuster & Wroldsen, supra note 45, at 146.
238. See Examination Guide 1-19: Examination of Marks for Cannabis and Cannabis-
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regulation was uncertain.239 Firms seeking Δ8-THC registrations have followed this
approach by, for instance, making absolute statements about the legality of their
products when the relevant law is not so clear. For example, one pending application
claims Δ8-THC “products that are legal in concordance with the 2018 farm bill.”240
This mimics a successful CBD-applicant’s arguments that their products were “legal
in interstate commerce,” despite the uncertainty surrounding CBD’s legal status at
that time.241 Whether such behaviors will ultimately prove successful is uncertain.
However, given the strategic value of Δ8-THC trademark registrations described
above and the significant arguments that these marks should be registered,242 it can
be expected that firms will continue to pursue these applications.
B. Potential Benefits for the Consuming Public
Beyond private, strategic benefits, federal registration of Δ8-THC trademarks can
create pro-social externalities that mitigate concerns about the drug. Commenters
worry about the market’s lack of government oversight.243 They allege that the want
of regulation disincentivizes investment in quality control, which ultimately leads to
products being sold that contain unwanted (and potentially dangerous) impurities.244
Relevant to this concern, prior research argues that a firm’s ability to secure
trademark protection encourages the production of high-quality goods.245 This
subsection addresses the intersection of these issues.

Related Goods and Services After Enactment of the 2018 Farm Bill, supra note 49.
239. Schuster & Wroldsen, supra note 45, at 148 (“Under current law, these statements
[about CBD’s legal status] are likely legally incorrect, but the ambiguous state of the law at
the time allowed firms to make questionable assertions, such as these, to obtain federal
trademarks.”).
240. U.S. Trademark Application Serial No. 97,124,420 (filed Nov. 15, 2021). Similarly,
some applicants claiming hemp-derived products seem to assert legality by stating that their
products contain less than 0.3% Δ8-THC. See U.S. Trademark Application Serial No.
97,163,491 (filed Dec. 9, 2021); U.S Trademark Application Serial No. 97,124,355 (filed Nov.
15, 2021). This is particularly curious given that there is no legal rule explicitly exempting
low-level Δ8-THC. Whether this is due to a misunderstanding or an attempt to confuse the
situation is unclear.
241. U.S. Trademark Application Serial No. 86,315,166 Office Action Response (dated
Oct. 31, 2014), Registration Certificate (dated Aug. 29, 2016). The DEA would later foreclose
this avenue of argument. 81 Fed. Reg. 90194, 90194–96 (Dec. 14, 2016).
242. See supra Sections 0.0, 0.
243. See Timmen L. Cermak, 4 Things to Know About Delta-8-THC, the New Cannabis
Drug, PSYCH. TODAY (Jan. 20, 2022), https://www.psychologytoday.com/us/blog/healingaddiction/202201/4-things-know-about-delta-8-thc-the-new-cannabis-drug [https://perma.cc/
4NDC-WHUJ] (describing the “lack of regulation” of 8-THC); see also Kaitlin Sullivan,
Delta-8 THC Is Legal in Many States, but Some Want to Ban It, NBC NEWS (June 28, 2021,
8:10 AM), https://www.nbcnews.com/health/health-news/delta-8-thc-legal-many-statessome-want-ban-it-n1272270 [https://perma.cc/A62X-G56G] (describing the sale of
unregulated 8-THC products as a possible “public health risk”).
244. Cermak, supra note 243 (“The lack of regulation raises concerns about inaccurate
labeling and contaminants.”).
245. Katya Assaf, The Dilution of Culture and the Law of Trademarks, 49 IDEA 1, 77
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As discussed previously, (arguably) legal Δ8-THC comes from hemp246—which
itself is legal under the 2018 Farm Bill.247 However, given Δ8-THC’s relatively low
concentration in most hemp, firms commonly create it through chemical alteration
of CBD that has been extracted from legal hemp.248 These chemical reactions can
potentially introduce unwanted side products.
While still a nascent market, evidence exists that some Δ8-THC goods do in fact
contain these unwanted side products.249 One study evaluated twenty-seven different
types of Δ8-THC from multiple manufacturers and found that each of them contained
“reaction side-products, including heavy metals.”250 The U.S. Food and Drug
Administration echoes these concerns, stating that “delta-8 THC product[s] may
have potentially harmful by-products.”251
Additional criticisms assert that Δ8-THC firms are intentionally adulterating their
wares with “cutting agents.”252 These agents are added to drugs to enhance the
product’s volume by diluting the relevant chemical253 or to boost the effect of the

(2008) (“Particularly, trademark rights are granted in order to encourage trademark owners
to invest in the quality of their goods and services, thereby creating and maintaining the
goodwill of their businesses.”); Stephanie M. Greene, Sorting Out “Fair Use” and
“Likelihood of Confusion” in Trademark Law, 43 AM. BUS. L.J. 43, 70 (2006); Julie Manning
Magid, Anthony D. Cox & Dena S. Cox, Quantifying Brand Image: Empirical Evidence of
Trademark Dilution, 43 AM. BUS. L.J. 1, 2 (2006).
246. See supra notes 3–4 and accompanying text (discussing the legality of Δ8-THC;
Controlled Substances: Alphabetical Order, supra note 24 (listing Δ8-THC as a Schedule I
drug).
247. 7 U.S.C.A. § 1639o (West).
248. McWilliams, Goff & Williams, supra note 2 (“Delta-8 THC, as opposed to delta-9
THC, is a cannabinoid usually found in very trace amounts in cannabis plants.”); Erickson,
supra note 66; Leas, supra note 3 (“Because CBD isomers are similar in structure to THC
isomers, they can be converted to THC isomers through a relatively simple series of chemical
reactions. The main method of converting CBD to delta-8-THC yields a solution containing
delta-8-THC and delta-9-THC as well as other byproducts from the associated reactions. This
solution can be further processed to remove delta-9-THC and then added to various consumer
goods for consumption or application.”).
249. Lester Black, How Mitch McConnell Accidentally Created an Unregulated THC
Market, FIVETHIRTYEIGHT (Oct. 18, 2021), https://fivethirtyeight.com/features/how-mitchmcconnell-accidentally-created-an-unregulated-thc-market/ [https://perma.cc/W4WT-YUE5]
(describing the presence of side products in Δ8-THC production).
250. Cermak, supra note 243 (“The authors investigated 27 delta-8 products from 10
brands and found none of them were accurately labeled, 11 contained unlabeled cutting agents,
and all contained reaction side-products, including heavy metals.”).
251. 5 Things to Know About Delta-8 Tetrahydrocannabinol – Delta-8 THC, supra note
197.
252. Sullivan, supra note 243 (“There is still very little known about delta-8 THC itself
and in an unregulated market, products that contain the compound can easily be cut with toxic
materials consumers have no way of knowing about.”)
253. Julian Broséus, Natacha Gentile & Pierre Esseivaetet, The Cutting of Cocaine and
Heroin: A Critical Review, 262 FORENSIC SCI. INT’L 73, 74 (2016) (“Typically, cutting agents
refer to diluents (pharmacologically inactive and readily available substances) and adulterants
(pharmacologically active substances, usually more expensive or less available than
diluents).”) (emphasis omitted).
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substance.254 In a largely unregulated market, consumers may intend to obtain “pure”
Δ8-THC, but instead might purchase a product laden with a variety of unlabeled or
unwanted chemical additives.255
Federal- and state-level regulation of Δ8-THC manufacture and distribution is an
obvious answer to several of the above concerns. However, registering trademarks
for Δ8-THC can bring private financial interests into line with the public goal of
reducing impurities. At present, firms in this market have relatively little incentive
to attempt to garner goodwill in a trademark. The lack of federal trademark
registration encourages other firms to free ride on any positive brand recognition.256
Restated, why would a firm try to make an outstanding product (i.e., Δ8-THC that is
free of impurities) if others are likely to sell inferior wares using their brand? Not
only does this undercut their sales, but it also sullies their trademark by creating
associations with another’s inferior products.
The trademark system addresses this problem by recognizing firms’ exclusive
rights in their marks.257 This prevents the free-riding problems described above. And
in turn, companies are encouraged to invest in the manufacture of quality products
and creation of firm goodwill, since others will not be able to appropriate their
trademarks without being sued for infringing a federally registered mark.
Through this mechanism, the incentive structure presented to private firms is
brought into line with public policy. Government oversight may serve to reduce
impurities in Δ8-THC products, but private financial gain arising from goodwill in a
brand can simultaneously incentivize Δ8-THC firms to do the same. Companies are
encouraged to sell pure products if they can capture any resultant goodwill in a
trademark that they have the exclusive rights to use. Thus, beyond the private
benefits discussed previously, the federal registration of Δ8-THC trademarks can
likewise create social benefits.
CONCLUSION
The intersection of cannabis and trademark law presents a variety of uncertain
legal issues and novel policy considerations. In recent years, difficult questions

254. Jeffrey D. Pope, Olaf H. Drummer & Hans G. Schneider, The Cocaine Cutting Agent
Levamisole is Frequently Detected in Cocaine Users, 50 PATHOLOGY 536, 536 (2018)
(“Cutting agents are used for economic reasons, but also to enhance or mimic the target
substance and to aid in the administration of the drug.”).
255. Sullivan, supra note 243 (“‘It’s not delta-8 that’s dangerous, it’s what it could be
mixed with in an unregulated market,’ said Steven Hawkins, CEO of the U.S. Cannabis
Council, a trade group that represents state-licensed cannabis companies and legalization
advocates.”).
256. It is possible that firms engaged in commerce in the Δ8-THC market may have some
rights under common law (i.e., un-registered rights). However, these rights will be limited.
For instance, a mark that is not registered at the federal level does not enjoy nationwide
constructive use. See 15 U.S.C. § 1057(c) (2012).
257. Assaf, supra note 196, at 77 (“Particularly, trademark rights are granted in order
to encourage trademark owners to invest in the quality of their goods and services, thereby
creating and maintaining the goodwill of their businesses.”); Greene, supra note 245, at 70;
Magid, Cox & Cox, supra note 245, at 2.
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regarding registration of trademarks for cannabis derivatives have been presented to
the USPTO. The most current challenge arose with regard to Δ8-THC goods. In
response, the Trademark Office presently rejects all applications associated with the
drug because it is not legal for use in commerce. This Article presents several reasons
why this approach is questionable.
Initially, the DEA and federal courts have both opined that Δ8-THC is legal, so
long as it is sourced from hemp.258 A critical reading of the DEA’s opinion letter on
the issue shows this conclusion to be true, regardless of if Δ8-THC molecules are
extracted from hemp or if the Δ8-THC is created by chemical alteration of CBD
extracted from hemp.259 While neither of these determinations are binding on the
USPTO, its own guidelines suggest deference to conclusions reached by relevant
administrative agencies and the courts.260 This strongly supports the position that Δ8THC marks should be registered.261
This conclusion has substantial public and private significance. With regard to
private concerns, Section 0.0 employed prior law and strategy research to explore
the immediate and future strategic benefits arising from Δ8-THC registrations.
Indeed, these gains explain why firms are willing to admit to selling Δ8-THC in a
trademark application, despite some uncertainty if such sales are legal. Moreover, a
willingness to register these marks can bring about social gains. Concerns regarding
impurities in Δ8-THC goods can be mitigated by incentivizing firms to generate high
quality products to enhance value in their federally registered trademarks. This gain
can, of course, only arise if the Trademark Office will register these marks.

258. See Letter from Terrence L. Boos to Donna C. Yeatman, supra note 65; AK Futures
LLC v. Boyd St. Distro, LLC, 35 F.4th 682, 692 (9th Cir. 2022).
259. See supra notes 178–185 and accompanying text.
260. See supra notes 186–190 and accompanying text.
261. As discussed throughout, this article only addresses issues associated with the
Controlled Substances Act. Other legal issues could potentially be raised. See supra note 8.

